

CITATION REPORT

List of articles citing

Improved survival in multiple myeloma and the impact of novel therapies

DOI: 10.1182/blood-2007-10-116129
Blood, 2008, 111, 2516-20.

Source: <https://exaly.com/paper-pdf/44523110/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1915	Efficacy of lenalidomide in association with cyclophosphamide and dexamethasone in multiple myeloma patient with bilateral retro-orbital localisation. 2013 , 7, 331		1
1914	Role of allogeneic stem cell transplantation in multiple myeloma. 2008 , 3, 99-106		3
1913	Lenalidomide: towards a new standard in the optimal management of multiple myeloma. 2008 , 32, S20-S24		
1912	Current Awareness in Hematological Oncology. 2008 , 26, 184-191		
1911	Pathogenesis and treatment of renal failure in multiple myeloma. 2008 , 22, 1485-93		215
1910	Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. 2008 , 22, 1767-72		40
1909	Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma. 2008 , 99, 2309-14		27
1908	The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. 2008 , 143, 46-53		91
1907	Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. 2008 , 143, 537-40		74
1906	Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. 2008 , 143, 511-9		49
1905	Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy. 2008 , 8, 294-9		8
1904	Lymphoid malignancies: a decade and a half of dramatic improvements in outcome. 2008 , 8 Suppl 4, S126-7		1
1903	Practical considerations for multiple myeloma: an overview of recent data and current options. 2008 , 8 Suppl 4, S144-8		1
1902	Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. <i>Blood</i> , 2008 , 112, 4445-51	2.2	149
1901	Myeloma therapy: 25 years forward--immune modulation then and now. 2008 , 26, 4698-700		3
1900	Prognostic factors for multiple myeloma in the era of novel agents. 2008 , 19 Suppl 7, vii117-20		20
1899	Treatment of myeloma--are we making progress?. 2008 , 359, 964-6		12

1898	Crossover confusion: MPT still best. <i>Blood</i> , 2008 , 112, 2998-9	2.2	2
1897	Many facets of bortezomib resistance/susceptibility. <i>Blood</i> , 2008 , 112, 2177-8	2.2	69
1896	Recent changes in myeloma therapies have decreased patient mortality. 2008 , 5, 303-303		
1895	Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. 2008 , 93, 1908-11		100
1894	TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA. 26-36		
1893	Advances in therapy of multiple myeloma. 2008 , 20, 697-704		25
1892	Changing paradigms in the treatment of multiple myeloma. 2009 , 94, 163-6		16
1891	Therapeutic Options in Multiple Myeloma: Focus on Bortezomib. 2009 , 1, CMT.S2119		
1890	Novel therapies in the treatment of multiple myeloma. 2009 , 7, 947-60		28
1889	Supportive therapies in multiple myeloma. 2009 , 7, 971-9		3
1888	Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 2009 , 27, 5001-7		42
1887	The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. 2009 , 20, 1303-17		171
1886	Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry. 2009 , 122, 200-10		27
1885	Relapse/Refractory myeloma patient: potential treatment guidelines. 2009 , 27, 5676-7		11
1884	Converting tumor-specific markers into reporters of oncolytic virus infection. 2009 , 17, 1395-403		16
1883	Antibody-maytansinoid conjugates for the treatment of myeloma. 2009 , 1, 548-51		52
1882	Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma. 2009 , 6, 247-8		4
1881	Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma. 2009 , 15, 520-31		25

1880	Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. 2009 , 27, 5008-14	252
1879	Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. 2009 , 16, 309-23	197
1878	Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 2009 , 625, 6-22	18
1877	Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. 2009 , 84, 799-802	71
1876	Novel agents in myeloma: an exciting saga. 2009 , 115, 236-42	4
1875	Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. 2009 , 115, 5734-9	57
1874	Centrosomes and myeloma; aneuploidy and proliferation. 2009 , 50, 697-707	11
1873	Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma. 2009 , 89, 636-41	11
1872	Targeted therapies in multiple myeloma. 2009 , 4, 23-36	29
1871	Continued survival gains in recent years among critically ill myeloma patients. 2009 , 35, 512-8	91
1870	Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. 2009 , 88, 1161-8	93
1869	High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. 2009 , 144, 169-75	91
1868	Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. 2009 , 144, 86-94	170
1867	Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. 2009 , 145, 681-708	26
1866	Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800. 2009 , 147, 319-27	15
1865	The research mission in myeloma. 2009 , 23, 422-3; author reply 423-4	2
1864	Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. 2009 , 23, 574-80	162
1863	Treatment of newly diagnosed myeloma. 2009 , 23, 449-56	74

1862	Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. 2009 , 23, 961-70	63
1861	Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). 2009 , 23, 1152-7	165
1860	The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. 2009 , 23, 1894-903	45
1859	Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. 2009 , 23, 2147-52	307
1858	Proteasome inhibitors in the treatment of multiple myeloma. 2009 , 23, 1964-79	140
1857	Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. 2009 , 23, 1337-41	281
1856	In pursuit of the allo-immune response in multiple myeloma: where do we go from here?. 2009 , 43, 91-9	7
1855	Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. 2009 , 33, e145-9	11
1854	Unusual myeloma relapse after thalidomide therapy: the dark side of the moon?. 2009 , 33, 1164-5	4
1853	Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs). 2009 , 10, 1-15	6
1852	Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. 2009 , 15, 463-70	46
1851	Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. 2009 , 15, 1386-93	16
1850	Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report. 2009 , 41, 4407-10	28
1849	Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transplant. 2009 , 15, 686-93	17
1848	Treatment of multiple myeloma: a comprehensive review. 2009 , 9, 278-88	117
1847	Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse. 2009 , 9, 436-42	10
1846	Bortezomib and Waldenstrom's macroglobulinemia. 2009 , 10, 909-16	8
1845	Novel therapies for relapsed myeloma. 2009 , 578-86	18

1844	New generation pharmacotherapy in elderly multiple myeloma patients. 2009 , 10, 81-98		3
1843	Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. 2009 , 46, 166-75		52
1842	Multiple myeloma. 2009 , 374, 324-39		605
1841	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. 2009 , 84, 1095-110		199
1840	Stem cell transplantation for multiple myeloma. 2009 , 21, 162-70		14
1839	Bibliography. Current world literature. 2009 , 21, 177-89		
1838	Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates. 2009 , 15, 473-8		3
1837	Integrating novel therapies in the transplant paradigm. 2009 , 15, 479-84		3
1836	First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective. 2009 , 10, 906-22		6
1835	Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. <i>Blood</i> , 2009 , 113, 3781-91	2.2	66
1834	Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). <i>Blood</i> , 2009 , 113, 4137-43	2.2	109
1833	Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. <i>Blood</i> , 2009 , 114, 522-5	2.2	160
1832	Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. <i>Blood</i> , 2009 , 114, 772-8	2.2	130
1831	Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. <i>Blood</i> , 2009 , 114, 518-21	2.2	118
1830	Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2009 , 114, 3276-84	2.2	31
1829	How I treat multiple myeloma in younger patients. <i>Blood</i> , 2009 , 114, 5436-43	2.2	116
1828	Newly diagnosed multiple myeloma in Taiwan: the evolution of therapy, stem cell transplantation and new treatment agents. 2009 , 2, 385-93		3
1827	NCCN clinical practice guidelines in oncology: multiple myeloma. 2009 , 7, 908-42		76

1826	Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. 2009 , 94, 270-5		107
1825	Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer. 2009 , 6, 248-50		4
1824	Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. 2010 , 95, 785-93		77
1823	In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. 2010 , 95, 794-803		133
1822	Drug-mediated and cellular immunotherapy in multiple myeloma. 2010 , 2, 243-55		10
1821	The Belgian 2010 consensus recommendations for the treatment of multiple myeloma. 2010 , 65, 252-64		
1820	The prognostic value of F-18 fluorodeoxyglucose bone marrow uptake in patients with recent diagnosis of multiple myeloma: a comparative study with Tc-99m sestamibi. 2010 , 35, 1-5		19
1819	[Molecular-targeted therapy of multiple myeloma]. 2010 , 99, 132-9		
1818	Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation. 2010 , 2010, 310-3		9
1817	Busulfan 12 mg/kg plus melphalan 140 mg/m ² versus melphalan 200 mg/m ² as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. 2010 , 95, 1913-20		83
1816	A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. 2010 , 95, 845-8		115
1815	Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. <i>Blood</i> , 2010 , 115, 3655-63	2.2	102
1814	Melphalan 200 mg/m ² versus melphalan 100 mg/m ² in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. <i>Blood</i> , 2010 , 115, 1873-9	2.2	71
1813	Kidney disease associated with plasma cell dyscrasias. <i>Blood</i> , 2010 , 116, 1397-404	2.2	40
1812	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. <i>Blood</i> , 2010 , 116, 3743-50	2.2	91
1811	Racial disparities in incidence and outcome in multiple myeloma: a population-based study. <i>Blood</i> , 2010 , 116, 5501-6	2.2	224
1810	Myeloma: making sense of a complex blood cancer. 2010 , 19, 1415-21		2
1809	Leptomeningeal myeloma as the sole manifestation of relapse: an unusual presentation. 2010 , 339, 81-2		4

1808	Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. 2010 , 28, 2259-66	352
1807	Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. 2010 , 89, 1133-40	50
1806	Therapieoptionen im Rezidiv des multiplen Myeloms. 2010 , 16, 282-288	
1805	Konventionelle Behandlung von Patienten mit multiple Myelom. 2010 , 16, 274-281	
1804	Austrian consensus recommendations for the treatment of patients with multiple myeloma. 2010 , 3, 7-10	1
1803	Treatment of newly diagnosed multiple myeloma: advances in current therapy. 2010 , 27 Suppl 1, S14-24	9
1802	Future directions in immunomodulatory therapy. 2010 , 27 Suppl 1, S62-6	0
1801	Advances in treatment for relapses and refractory multiple myeloma. 2010 , 27 Suppl 1, S25-42	9
1800	The evolution and impact of therapy in multiple myeloma. 2010 , 27 Suppl 1, S1-6	32
1799	Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka. 2010 , 92, 579-86	11
1798	Improving induction therapy in multiple myeloma. 2010 , 5, 119-28	4
1797	The DAC system and associations with multiple myeloma. 2010 , 28 Suppl 1, S28-35	14
1796	Trends in the incidence and survival of multiple myeloma in South East England 1985-2004. 2010 , 10, 74	19
1795	New treatments for myeloma. 2010 , 77, 20-6	3
1794	Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis. 2010 , 84, 412-20	22
1793	Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004. 2010 , 85, 209-16	12
1792	High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. 2010 , 85, 114-9	82
1791	Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs. 2010 , 85, 181-91	13

1790	Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. 2010 , 116, 3143-51	27
1789	Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis. 2010 , 85, 95-6	17
1788	A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. 2010 , 85, 409-13	13
1787	Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. 2010 , 85, 737-40	17
1786	Nouvelles thérapies du myélome. 2010 , 77, 21-27	3
1785	Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. 2010 , 34, 1111-8	49
1784	How best to use new therapies in multiple myeloma. 2010 , 24, 91-100	10
1783	Long-term disease control in multiple myeloma: the impact of the dual mechanism of action of lenalidomide. Introduction and overview. 2010 , 24 Suppl 1, S1-3	
1782	Lenalidomide: an update on evidence from clinical trials. 2010 , 24 Suppl 1, S21-6	8
1781	Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies. 2010 , 24 Suppl 1, S27-32	15
1780	Concluding remarks and future directions. 2010 , 24 Suppl 1, S33-4	
1779	Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. 2010 , 148, 853-8	2
1778	Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. 2010 , 149, 529-36	48
1777	Plasma cell leukaemia and other aggressive plasma cell malignancies. 2010 , 150, 418-27	31
1776	Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy. 2010 , 103, 1580-7	29
1775	Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. 2010 , 24, 1350-6	68
1774	Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. 2010 , 24, 1406-11	38
1773	Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. 2010 , 24, 1555-65	24

1772	Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. 2010 , 24, 1037-42		33
1771	A case study progression to multiple myeloma. 2010 , 14, 419-22		
1770	Plasma cell neoplasms. 244-265		
1769	The treatment of multiple myeloma patients not eligible for asct. 2010 , 2, e2010009		2
1768	Survival and years of life lost in different age cohorts of patients with multiple myeloma. 2010 , 28, 1599-605		113
1767	Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. 2010 , 28, 800-7		146
1766	Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. 2010 , 28, 830-4		144
1765	Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. 2010 , 28, 2077-84		223
1764	The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib. 2010 , 9, 1574-82		4
1763	Myeloma and the Kidney. 2010 , 761-769		1
1762	Multiple myeloma precursor disease. 2010 , 304, 2397-404		37
1761	Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. 2010 , 28, 2612-24		161
1760	Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. 2010 , 3, 165-74		10
1759	Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT. 2010 , 30, 127-42		109
1758	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2010 , 116, 679-86	2.2	680
1757	Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. 2010 , 25, 419-26		90
1756	Current multiple myeloma treatment strategies with novel agents: a European perspective. 2010 , 15, 6-25		77
1755	Renal insufficiency and failure. 2010 , 2010, 431-6		21

1754	Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. 2010 , 21, 325-330	296
1753	Lenalidomide in multiple myeloma: current role and future directions. 2010 , 11, 829-42	10
1752	Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapies. 2010 , 85, 532-7	52
1751	Conflicts of interest, authorship, and disclosures in industry-related scientific publications. 2010 , 85, 197-9; author reply 201-4	2
1750	Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. 2010 , 85, 933-42	88
1749	The current status and future of multiple myeloma in the clinic. 2010 , 10, 28-43	20
1748	Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. 2010 , 10, 149-51	28
1747	Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future. 2010 , 10, 248-57	15
1746	The annual meeting of the American Society of Clinical Oncology. June 4-8, 2010; Chicago, IL. 2010 , 10, 323-30	
1745	Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials. 2010 , 10, 353-60	4
1744	Ten years of improvement in the management of multiple myeloma: 2000-2010. 2010 , 10, 424-42	22
1743	Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. 2010 , 28, 4976-84	290
1742	Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. 2010 , 46, 160-9	65
1741	Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. 2010 , 46, 1790-9	28
1740	Home administration of bortezomib: making a difference to myeloma patients' lives. 2010 , 14, 134-6	6
1739	Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. 2010 , 16, 395-402	46
1738	Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. 2010 , 16, 1122-9	31
1737	International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. 2010 , 28, 4521-30	136

1736	Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma. 2010 , 125 Suppl 2, S96-102	34
1735	Clinical management of myeloma--state of the art. 2010 , 36 Suppl 2, S1-2	1
1734	Multiple myeloma - current issues and controversies. 2010 , 36 Suppl 2, S3-11	35
1733	Presentation and risk stratification--improving prognosis for patients with multiple myeloma. 2010 , 36 Suppl 2, S12-7	14
1732	Role of new treatment approaches in defining treatment goals in multiple myeloma--the ultimate goal is extended survival. 2010 , 36 Suppl 2, S18-23	24
1731	Management of treatment-related adverse events in patients with multiple myeloma. 2010 , 36 Suppl 2, S24-32	53
1730	Optimising patient outcomes in myeloma. 2010 , 36 Suppl 2, S33-5	4
1729	Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. 2010 , 51, 2084-91	30
1728	Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. 2010 , 51, 1444-9	3
1727	Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma. 2010 , 51, 2159-70	18
1726	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. 2010 , 51, 1424-43	43
1725	CCR1 as a target for multiple myeloma. 2011 , 15, 1037-47	32
1724	Epidemiology of multiple myeloma and the role of M-band detection on serum electrophoresis in a small developing country. A retrospective study. 2011 , 117, 236-40	2
1723	Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. 2011 , 52, 1262-70	11
1722	Managing multiple myeloma in the elderly: are we making progress?. 2011 , 4, 301-15	6
1721	Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. 2011 , 96, 284-90	172
1720	The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information. 2011 , 29, 269-85	13
1719	Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib. 2011 , 14, 690-7	26

1718	Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. 2011 , 86, 12-8	141
1717	High-risk multiple myeloma: does it still exist?. 2011 , 11 Suppl 1, S70-6	3
1716	Management of myeloma: an Italian perspective. 2011 , 11 Suppl 1, S82-6	
1715	Paraneoplastic cutaneous leukocytoclastic vasculitis disclosing multiple myeloma: a case report. 2011 , 11, 373-4	8
1714	Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma. 2011 , 11, 409-13	28
1713	Multiple myeloma. 2011 , 62, 249-64	99
1712	Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. 2011 , 52, 2299-303	26
1711	Mylabris Phalerata (Chinese Blister Beetle) on Hematological Malignancies. 2011 , 375-388	2
1710	Plasma Cell Disorders. 2011 , 287-306	
1709	Bortezomib for previously untreated multiple myeloma. 2011 , 4, 381-98	3
1708	The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. 2011 , 25, 1533-42	98
1707	Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma. 2011 , 14, 672-8	8
1706	Optimal management of cancer treatment-induced bone loss: considerations for elderly patients. 2011 , 28, 867-83	11
1705	Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. 2011 , 29, 1916-23	66
1704	How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions. 2011 , 20, 779-93	7
1703	Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. 2011 , 4, 51-60	21
1702	Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma. 2011 , 412, 562-8	8
1701	Treatment of relapsed and refractory multiple myeloma in the era of novel agents. 2011 , 37, 266-83	62

1700	Osteoblast function in myeloma. 2011 , 48, 135-40	60
1699	Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. 2011 , 47, 814-8	14
1698	Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. 2011 , 17, 1638-45	48
1697	Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. 2011 , 52, 560-6	10
1696	Pomalidomide therapy for myeloma. 2011 , 20, 691-700	27
1695	Recent advances in myeloma treatment. 2011 , 44, 223-9	3
1694	Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. 2011 , 12, 263-72	72
1693	Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. 2011 , 12, 431-40	73 ¹
1692	Multiple myeloma and the road to personalised medicine. 2011 , 12, 617-9	44
1691	Multiple myeloma: current perspectives. 2011 , 31, 699-724, x	6
1690	Multiple myeloma. 2011 , 364, 1046-60	1724
1689	Multiple myeloma: five-year experience at a University Hospital. 2011 , 9, 145-50	1
1688	Autologous stem-cell transplantation for multiple myeloma: a Brazilian institution experience in 15 years of follow-up. 2011 , 9, 119-23	2
1687	Management of relapsed and relapsed/refractory multiple myeloma. 2011 , 9, 1209-16	20
1686	Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. 2011 , 6, 43-57	36
1685	Activation of coagulation by a thalidomide-based regimen. 2011 , 22, 532-40	13
1684	Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents. 2011 , 8, 415-429	3
1683	Quinone methide tripterine, celastrol, induces apoptosis in human myeloma cells via NF- κ B pathway. 2011 , 39, 1117-22	17

1682	Pharmaceutical inhibition of glycogen synthetase kinase-3 β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model. <i>Blood</i> , 2011 , 117, 1641-51	2.2	32
1681	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011 , 117, 6063-73	2.2	234
1680	Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. <i>Blood</i> , 2011 , 118, 1979-88	2.2	69
1679	Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. <i>Blood</i> , 2011 , 117, 6721-7	2.2	97
1678	Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. <i>Blood</i> , 2011 , 118, 2970-5	2.2	170
1677	Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. <i>Blood</i> , 2011 , 118, 1763-5	2.2	53
1676	Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. <i>Blood</i> , 2011 , 118, 4771-9	2.2	453
1675	Approach to the treatment of multiple myeloma: a clash of philosophies. <i>Blood</i> , 2011 , 118, 3205-11	2.2	115
1674	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). <i>Blood</i> , 2011 , 118, 4519-29	2.2	267
1673	Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. <i>Blood</i> , 2011 , 118, 5989-95	2.2	357
1672	A third-generation IMiD for MM. <i>Blood</i> , 2011 , 118, 2931-2	2.2	10
1671	Evolving paradigms in the treatment of newly diagnosed multiple myeloma. 2011 , 9, 1186-96		8
1670	Guidelines for the diagnosis and management of multiple myeloma 2011. 2011 , 154, 32-75		224
1669	Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. 2011 , 153, 729-40		84
1668	Monoclonal antibodies in the treatment of multiple myeloma. 2011 , 154, 745-54		61
1667	Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. 2011 , 154, 755-62		17
1666	A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. 2011 , 155, 580-7		25
1665	Relapsed multiple myeloma in the UK prior to the introduction of novel agents--a response to Koleva et al. (2010). 2011 , 20, 697-9		

1664	Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors. 2011 , 86, 93-110	32
1663	Melphalan 100 mg/m ² with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation. 2011 , 87, 117-22	13
1662	Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy. 2011 , 87, 323-9	3
1661	Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model. 2011 , 11, 301	30
1660	Carfilzomib: a novel second-generation proteasome inhibitor. 2011 , 7, 607-12	56
1659	A reappraisal of immunoglobulin variable gene primers and its impact on assessing clonal relationships between PB B cells and BM plasma cells in AL amyloidosis. 2011 , 31, 1029-37	1
1658	Living with multiple myeloma: experiences of patients and their informal caregivers. 2011 , 19, 101-11	74
1657	Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. 2011 , 60, 985-97	30
1656	Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience. 2011 , 90, 115-6	6
1655	Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. 2011 , 90, 429-39	53
1654	Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma. 2011 , 90, 1441-7	2
1653	Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma. 2011 , 90, 1449-56	16
1652	Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. 2011 , 90, 1427-39	32
1651	Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. 2011 , 93, 351-360	18
1650	Update on risk stratification and treatment of newly diagnosed multiple myeloma. 2011 , 94, 310-320	29
1649	Bone anabolic agents for the treatment of multiple myeloma. 2011 , 4, 339-49	19
1648	Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. 2011 , 28 Suppl 1, 11-6	15
1647	Management of the adverse effects of lenalidomide in multiple myeloma. 2011 , 28 Suppl 1, 1-10	8

1646	Continued treatment with lenalidomide in multiple myeloma. 2011 , 28, 1-13	3
1645	Prolonged treatment with lenalidomide in relapsed and refractory multiple myeloma. 2011 , 28, 14-19	
1644	New immunomodulatory drugs in myeloma. 2011 , 6, 120-5	8
1643	Treatment of newly diagnosed myeloma in patients not eligible for transplantation. 2011 , 6, 113-9	6
1642	Treatment of newly diagnosed multiple myeloma in transplant-eligible patients. 2011 , 6, 104-12	9
1641	Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4. 2011 , 11, 394	13
1640	Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid. 2011 , 86, 25-30	17
1639	Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. 2011 , 86, 57-65	109
1638	No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years. 2011 , 86, 479-83	30
1637	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. 2011 , 86, 640-5	51
1636	Myeloma ASH 2010 highlights. 2011 , 86, 820-3	
1635	Prevalence of monoclonal gammopathy of undetermined significance in an elderly urban Korean population. 2011 , 86, 752-5	12
1634	The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens. 2011 , 117, 1884-90	13
1633	Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. 2011 , 117, 2136-44	51
1632	Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma. 2011 , 35, 147-51	13
1631	Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma. 2011 , 7, 135-43	4
1630	Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. 2011 , 37, 929-45	49
1629	Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (. 2011 , 52, 34-41	40

1628	Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. 2011 , 17, 1253-63	58
1627	Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. 2011 , 10, 2034-42	213
1626	Thyroid hormone is a MAPK-dependent growth factor for human myeloma cells acting via α 5 β 1 integrin. 2011 , 9, 1385-94	44
1625	Multiple Myeloma. 2011 ,	2
1624	Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. 2011 , 16, 011006	32
1623	Experimental approaches in the treatment of multiple myeloma. 2011 , 2, 213-30	2
1622	SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. 2011 , 17, 1382-93	185
1621	Bortezomib in patients with renal impairment. 2011 , 16, 200-8	5
1620	Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma. 2011 , 4, 1-9	2
1619	Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. 2011 , 25, 1620-6	20
1618	Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. 2011 , 25, 749-60	97
1617	Case records of the Massachusetts General Hospital: Case 29-2011: A 66-year-old woman with cardiac and renal failure. 2011 , 365, 1129-38	4
1616	Treatment of multiple myeloma. 2011 , 8, 479-91	205
1615	Oncogenomics to target myeloma in the bone marrow microenvironment. 2011 , 17, 1225-33	48
1614	New insights into therapeutic targets in myeloma. 2011 , 2011, 184-90	37
1613	The outcome of high-dose chemotherapy and auto-SCT in patients with multiple myeloma: a UK/Ireland and European benchmarking comparative analysis. 2011 , 46, 1210-8	6
1612	Survivorship care guidelines for patients living with multiple myeloma: consensus statements of the International Myeloma Foundation Nurse Leadership Board. 2011 , 15 Suppl, 5-8	16
1611	Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. 2011 , 29, 4243-9	107

1610	Reply to S.M. Sorscher et al. 2011 , 29, 2736-2737	2
1609	Routine health maintenance in patients living with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. 2011 , 15 Suppl, 25-40	11
1608	Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents. 2012 , 4, e39	8
1607	Onco-nephrology: AKI in the cancer patient. 2012 , 7, 1692-700	77
1606	Immunotherapy using dendritic cells against multiple myeloma: how to improve?. 2012 , 2012, 397648	25
1605	Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: a matter of undetermined significance. 2012 , 47, 1212-6	13
1604	Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. 2012 , 47, 1403-8	38
1603	Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. 2012 , 3, 117-24	29
1602	Identification of M protein from filter paper using serum protein and immunofixation electrophoresis. 2012 , 138, 604-8	2
1601	Role of autologous bone marrow transplant in multiple myeloma. 2012 , 24, 733-41	7
1600	European perspective on multiple myeloma treatment strategies: update following recent congresses. 2012 , 17, 592-606	43
1599	Multiple myeloma: improved outcomes with new therapeutic approaches. 2012 , 6, 330-6	16
1598	Incorporating monoclonal antibodies into the therapy of multiple myeloma. 2012 , 30, 1904-6	9
1597	How to select among available options for the treatment of multiple myeloma. 2012 , 23 Suppl 10, x334-8	4
1596	Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. 2012 , 97, 1761-7	210
1595	Clinical experience with thalidomide and lenalidomide in multiple myeloma. 2012 , 12, 372-90	7
1594	Emerging strategies for targeting cell adhesion in multiple myeloma. 2012 , 65, 143-89	10
1593	Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. 2012 , 47, 516-21	8

1592	Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved?. 2012 , 53, 1630-2		5
1591	Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. <i>Blood</i> , 2012 , 119, 4375-82	2.2	335
1590	Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. 2012 , 18, 2145-63		32
1589	Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. 2012 , 366, 1782-91		848
1588	Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation. 2012 , 26, 2286-96		24
1587	Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. 2012 , 2, e68		35
1586	RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma. 2012 , 11, 2600-9		23
1585	Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow		162
1584	The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. 2012 , 30, 445-52		111
1583	The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. 2012 , 11, 1781-8		44
1582	A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. 2012 , 26, 1675-80		31
1581	p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide. 2012 , 137, 208-12		20
1580	Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. 2012 , 8, 1209-22		8
1579	Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma. 2012 , 6, 1-10		7
1578	Immunogenic targets for specific immunotherapy in multiple myeloma. 2012 , 2012, 820394		9
1577	Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. 2012 , 5, 237-44		20
1576	Autologous stem cell transplant for AL amyloidosis. 2012 , 2012, 238961		6
1575	Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus. 2012 , 2012, 621958		15

1574	Defining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasias. 2012 , 120, c228-35		17
1573	Targeted therapy of multiple myeloma. 2012 , 17 Suppl 1, S125-8		5
1572	Targeted therapy of multiple myeloma: the changing paradigm at the beginning of the new millennium. 2012 , 12, 743-56		10
1571	Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide. 2012 , 24 Suppl 2, S3-11		13
1570	Thrombosis is associated with inferior survival in multiple myeloma. 2012 , 97, 1603-7		46
1569	Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies. 2012 , 24 Suppl 2, S13-20		1
1568	Clinical utility and implementation of gene-expression profiling in myeloma: current status and challenges. 2012 , 1, 133-146		
1567	[Case report; A case of multiple myeloma which cells gained multiple gene and chromosome aberrations and changed their morphology to plasmablastoid and lymphoblastoid during less than two years course]. 2012 , 101, 3236-8		
1566	Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. 2012 , 97, 784-91		43
1565	The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. 2012 , 97, 1101-9		34
1564	Novel therapies in monoclonal gammopathies. 2012 , 17 Suppl 1, S121-4		
1563	Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. 2012 , 97, 616-21		15
1562	KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. <i>Blood</i> , 2012 , 119, 1450-8	2.2	47
1561	Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. <i>Blood</i> , 2012 , 119, 6219-25; quiz 6399	2.2	92
1560	Second malignancies after multiple myeloma: from 1960s to 2010s. <i>Blood</i> , 2012 , 119, 2731-7	2.2	87
1559	Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. <i>Blood</i> , 2012 , 119, 4608-13	2.2	94
1558	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. <i>Blood</i> , 2012 , 119, 4860-7	2.2	108
1557	How I treat plasma cell leukemia. <i>Blood</i> , 2012 , 120, 2376-89	2.2	93

1556	A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2012 , 120, 4324-33	2.2	193
1555	Extending myeloma survival: targeting the seed and the soil. 2012 , 21, S16-7		1
1554	Dysproteinemias or light chain diseases. 2012 , 251-264		1
1553	Model of translational cancer research in multiple myeloma. 2012 , 103, 1907-12		4
1552	A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. 2012 , 159, 58-66		9 ²
1551	Sustained disease control in transplant-ineligible patients: the role of continuous therapy. 2012 , 36 Suppl 1, S19-26		2
1550	Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005. 2012 , 181, 1870-8		20
1549	Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMiDs. 2012 , 21, 1075-87		15
1548	Blockade of XBP1 splicing by inhibition of IRE1 β s a promising therapeutic option in multiple myeloma. <i>Blood</i> , 2012 , 119, 5772-81	2.2	296
1547	Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. 2012 , 16, 659-71		16
1546	ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells. 2012 , 586, 4311-8		20
1545	Wnt and Wnt inhibitors in bone metastasis. 2012 , 1, 101		22
1544	Myeloma kidney: improving clinical outcomes?. 2012 , 19, 342-51		9
1543	The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney. 2012 , 19, 324-32		6
1542	Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. 2012 , 18, 1540-51		47
1541	How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events. 2012 , 36 Suppl 1, S35-43		14
1540	The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. 2012 , 23, 722-729		20
1539	Emerging biological insights and novel treatment strategies in multiple myeloma. 2012 , 17, 407-38		12

1538	Management of myeloma-associated renal dysfunction in the era of novel therapies. 2012 , 5, 51-66; quiz 67-8		25
1537	Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. 2012 , 30, 1960-5		167
1536	A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. <i>Blood</i> , 2012 , 120, 552-9	2.2	288
1535	Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. 2012 , 53, 1714-21		24
1534	Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. 2012 , 53, 632-4		38
1533	The role of natural killer cells in immunity against multiple myeloma. 2012 , 53, 1666-76		53
1532	(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. 2012 , 91, 1779-84		15
1531	Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib. 2012 , 43, 858-64		13
1530	Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. 2012 , 18, 617-26		65
1529	Autologous stem cell transplantation and multiple myeloma cancer stem cells. 2012 , 18, S27-32		21
1528	Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. 2012 , 13, 473-94		13
1527	Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma - comparison between two different induction regimens. 2012 , 26, E549-54		1
1526	Latest advances and current challenges in the treatment of multiple myeloma. 2012 , 9, 135-43		165
1525	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. 2012 , 26, 149-57		580
1524	Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma. 2012 , 72, 2023-32		17
1523	Can we change the disease biology of multiple myeloma?. 2012 , 36 Suppl 1, S3-12		44
1522	First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. 2012 , 10, CD004626		17
1521	An historic perspective of proteasome inhibition. 2012 , 49, 196-206		12

1520	How to manage neutropenia in multiple myeloma. 2012 , 12, 5-11	33
1519	Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma. 2012 , 12, 186-90	2
1518	Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma. 2012 , 12, 325-9	5
1517	Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry. 2012 , 12, 423-32	32
1516	Bench-to-bedside translation of targeted therapies in multiple myeloma. 2012 , 9, 87-93	
1515	Carfilzomib for myeloma: proteasome inhibition with a different flavor?. 2012 , 9, 270-271	
1514	Bortezomib for myeloma: optimizing treatment strategies. 2012 , 9, 272-273	2
1513	The application and biology of immunomodulatory drugs (IMiDs) in cancer. 2012 , 136, 56-68	49
1512	Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma. 2012 , 36 Suppl 1, S13-8	8
1511	Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors. 2012 , 26, 2124-34	27
1510	Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma. 2012 , 1, 35	3
1509	Novel approaches for reducing free light chains in patients with myeloma kidney. 2012 , 8, 234-43	25
1508	Waldenström macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005. 2012 , 53, 1625-6	47
1507	The Centrosome. 2012 ,	9
1506	Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. 2012 , 26, 73-85	71
1505	Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. 2012 , 8, 1223-38	10
1504	Role of carfilzomib in the treatment of multiple myeloma. 2012 , 5, 361-72	14
1503	Novel agents and the paradigm of continuous treatment in multiple myeloma. 2012 , 36 Suppl 1, S1-2	3

1502	Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients. 2012 , 53, 2444-8	3
1501	Achieving an early myeloma response in patients with kidney impairment. 2012 , 19, 303-11	4
1500	The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. 2012 , 2, e89	62
1499	Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. 2012 , 53, 1820-3	103
1498	Lenalidomide for the treatment of relapsed and refractory multiple myeloma. 2012 , 4, 253-68	26
1497	Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma. 2012 , 4, e26	0
1496	Looking at CER from Medicare's perspective. 2012 , 18, S5-8	4
1495	Multiple Myeloma: Supportive Care Requirements and Coordination of Patient-Centered Care. 2012 , 18, S20-S25	
1494	Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation. 2012 , 18, 3697-704	49
1493	Emergence of central nervous system myeloma in the era of novel agents. 2012 , 30, 170-4	28
1492	Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. 2012 , 26, 199-213	66
1491	Lenalidomide after stem-cell transplantation for multiple myeloma. 2012 , 366, 1770-81	862
1490	Lenalidomide in multiple myeloma: Current status and future potential. 2012 , 87, 1089-95	19
1489	Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. 2012 , 118, 6105-9	52
1488	Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. 2012 , 72, 1395-406	77
1487	Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. 2012 , 90, 695-706	48
1486	Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma. 2012 , 95, 516-26	12
1485	Detection of serum tumor markers in multiple myeloma using the CLINPROT system. 2012 , 95, 668-74	11

1484	Continuous treatment with lenalidomide in multiple myeloma: a case report. 2012 , 5, 23-26	1
1483	Sustained response to single agent therapy with continuous lenalidomide in a pre-treated high-risk multiple myeloma patient. 2012 , 5, 27-29	0
1482	A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma. 2012 , 91, 1023-30	11
1481	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. 2012 , 91, 875-88	27
1480	Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation. 2012 , 156, 683-6	16
1479	A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. 2012 , 156, 326-33	45
1478	Genetic variations in multiple myeloma II: association with effect of treatment. 2012 , 88, 93-117	24
1477	The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. 2012 , 88, 406-15	19
1476	Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. 2012 , 89, 16-27	61
1475	The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group. 2012 , 89, 136-44	5
1474	Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. 2012 , 36, 1016-21	38
1473	Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. 2012 , 157, 553-63	18
1472	Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. 2012 , 158, 91-8	69
1471	Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. 2012 , 158, 472-80	49
1470	Non-cryopreserved hematopoietic stem cell transplantation in multiple myeloma, a single center experience. 2012 , 26, 117-22	18
1469	Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. 2012 , 118, 1574-84	79
1468	Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. 2012 , 87, 78-88	106
1467	Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. 2012 , 95, 64-70	39

1466	International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents. 2012 , 91, 93-102	4
1465	Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma. 2012 , 91, 257-69	6
1464	Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 2012 , 91, 419-26	9
1463	Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. 2013 , 31, 41-8	29
1462	A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. 2013 , 6, 41	30
1461	Genetic and Molecular Epidemiology of Multiple Myeloma. 2013 ,	
1460	Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. 2013 , 162, 483-8	70
1459	Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution. 2013 , 98, 1142-6	31
1458	Time-dependent endpoints as predictors of overall survival in multiple myeloma. 2013 , 13, 122	16
1457	A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors. 2013 , 13, 31	42
1456	Impact of genetic targets on cancer therapy. Forward. 2013 , 779, v-vi	1
1455	Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. 2013 , 139, 499-508	30
1454	Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens. 2013 , 97, 382-7	17
1453	Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen. 2013 , 97, 92-7	6
1452	Salvage second hematopoietic cell transplantation in myeloma. 2013 , 19, 760-6	87
1451	Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment. 2013 , 91, 399-410	36
1450	Intravoxel incoherent motion imaging for assessment of bone marrow infiltration of monoclonal plasma cell diseases. 2013 , 92, 1553-7	11
1449	Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation. 2013 , 92, 1271-80	3

1448	Advances in current treatment for patients with newly diagnosed multiple myeloma. 2013 , 2, S1-2	1
1447	Challenges in multiple myeloma diagnosis and treatment. 2013 , 2, S3-9	4
1446	Pomalidomide: first global approval. 2013 , 73, 595-604	28
1445	Immunotherapy strategies for multiple myeloma: the present and the future. 2013 , 5, 1005-20	3
1444	Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. 2013 , 46, 671-80	68
1443	Clinical translation in multiple myeloma: from bench to bedside. 2013 , 40, 549-53	7
1442	Initial treatment of nontransplant patients with multiple myeloma. 2013 , 40, 577-84	6
1441	Managing multiple myeloma patients with renal failure. 2013 , 15, 62-67	0
1440	Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma. 2013 , 19, 260-5	35
1439	Smoldering multiple myeloma requiring treatment: time for a new definition?. <i>Blood</i> , 2013 , 122, 4172-81.2	51
1438	Pomalidomide in the treatment of relapsed multiple myeloma. 2013 , 9, 939-48	3
1437	The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. 2013 , 27, 430-40	98
1436	International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. 2013 , 31, 2347-57	245
1435	Management of double-refractory multiple myeloma. 2013 , 8, 253-60	8
1434	Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. 2013 , 47, 1136-42	26
1433	Imaging of multiple myeloma: usefulness of MRI and PET/CT. 2013 , 34, 566-77	9
1432	Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. 2013 , 41, 1008-15	18
1431	Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels. 2013 , 91, 504-13	11

1430	Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains. 2013 , 162, 371-5	33
1429	Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. 2013 , 119, 2438-46	46
1428	Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. 2013 , 31, 3279-87	199
1427	Extramedullary disease in plasma cell myeloma: the iceberg phenomenon. 2013 , 48, 10-8	33
1426	Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. 2013 , 88 Suppl 1, S5-13	15
1425	Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales. 2013 , 14, 507-14	27
1424	[Therapy of multiple myeloma. What is confirmed?]. 2013 , 54, 1434, 1436-8, 1440-2	1
1423	Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategy. 2013 , 8, 277-83	3
1422	Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. 2013 , 3, e143	69
1421	Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. 2013 , 163, 40-6	71
1420	An old drug with a new future: bendamustine in multiple myeloma. 2013 , 14, 2263-80	12
1419	Current & Emerging Therapeutics for Multiple Myeloma. 2013 ,	
1418	Pleurocidin-family cationic antimicrobial peptides mediate lysis of multiple myeloma cells and impair the growth of multiple myeloma xenografts. 2013 , 54, 2255-62	14
1417	Molecular mechanisms of effectiveness of novel therapies in multiple myeloma. 2013 , 54, 229-41	14
1416	New insights, recent advances, and current challenges in the biological treatment of multiple myeloma. 2013 , 13 Suppl 1, S35-53	8
1415	Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. 2013 , 119, 3680-6	21
1414	Characterization of multiple myeloma vesicles by label-free relative quantitation. 2013 , 13, 3013-29	28
1413	Will the real myeloma please stand up?. 2013 , 27, 760-1	4

1412	Current treatments for renal failure due to multiple myeloma. 2013 , 14, 1477-95		27
1411	Una valutazione economica di due sequenze terapeutiche nel trattamento del mieloma multiplo ricaduto e/o refrattario. 2013 , 15, 1-8		
1410	Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. 2013 , 9, 1517-27		13
1409	Multiple myeloma: future directions in autologous transplantation and novel agents. 2013 , 19, S20-5		8
1408	Prognosis and Staging of Multiple Myeloma. 2013 , 615-636		2
1407	Diagnosis and Treatment of Multiple Myeloma. 2013 , 637-663		2
1406	Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. <i>Blood</i> , 2013 , 121, 884-92	2.2	141
1405	Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey. 2013 , 21, 599-607		34
1404	Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma. 2013 , 88, 102-6		5
1403	Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. 2013 , 40, 634-51		34
1402	Role of consolidation/maintenance therapy in multiple myeloma. 2013 , 13 Suppl 2, S349-54		7
1401	New insights on the function of SCF ubiquitin E3 ligases in the lung. 2013 , 25, 1792-8		14
1400	The future of drug development and therapy in myeloma. 2013 , 40, 652-8		6
1399	Novel generation of agents with proven clinical activity in multiple myeloma. 2013 , 40, 618-33		20
1398	Sequence of novel agents in multiple myeloma: an instrumental variable analysis. 2013 , 37, 1077-82		1
1397	New developments in post-transplant maintenance treatment of multiple myeloma. 2013 , 40, 602-9		8
1396	Translational research w szpiczaku plazmocytowym polskibzanslna przyspieszenie?. 2013 , 44, 196-199		
1395	Pomalidomide: new immunomodulatory agent with potent antiproliferative effects. 2013 , 88 Suppl 1, S36-44		24

1394	Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies. 2013 , 19, 1661-9	13
1393	Hyperferritinemia in stem cell transplantation. 2013 , 19, 336-7	4
1392	New hope for relapsed and refractory multiple myeloma. 2013 , 14, 1028-1029	5
1391	Digging deeper with allogeneic transplantation in multiple myeloma. 2013 , 19, 335-6	3
1390	Immunomodulatory agents changing the landscape of multiple myeloma treatment. 2013 , 88 Suppl 1, S1-4	3
1389	Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patients. 2013 , 37, 1527-31	2
1388	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. 2013 , 88, 360-76	341
1387	Continuous treatment in multiple myeloma: the future?. 2013 , 49, 147-50	5
1386	The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. 2013 , 37, 1070-6	12
1385	Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. 2013 , 6, 2	35
1384	Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. 2013 , 54, 1658-64	54
1383	Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. 2013 , 88, 226-35	92
1382	History of Multiple Myeloma. 2013 , 521-533	
1381	Cytokines and Signal Transduction in Multiple Myeloma. 2013 , 535-546	2
1380	Targeted therapy of multiple myeloma. 2013 , 779, 197-221	18
1379	Immunomodulatory drugs in multiple myeloma. 2013 , 6, 69-82	37
1378	Anticancer activity in human multiple myeloma U266 cells: synergy between cryptotanshinone and arsenic trioxide. 2013 , 5, 871-8	20
1377	Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis. 2013 , 14, 144-55	2

1376	Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib. 2013 , 37, 641-6	10
1375	Proteasome inhibitors in the treatment of multiple myeloma. 2013 , 13, 339-58	37
1374	Evolving therapeutic paradigms for multiple myeloma: back to the future. 2013 , 54, 451-63	12
1373	Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. 2013 , 48, 1302-7	58
1372	Perspectives in the treatment of multiple myeloma. 2013 , 13 Suppl 1, S1-22	17
1371	The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78. 2013 , 8, e63414	48
1370	Novel immunomodulatory compounds in multiple myeloma. 2013 , 22, 207-15	8
1369	Reduced-intensity hematopoietic stem cell transplants for malignancies: harnessing the graft-versus-tumor effect. 2013 , 64, 101-17	19
1368	Novel lenalidomide-based combinations for treatment of multiple myeloma. 2013 , 85, 9-20	9
1367	Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. 2013 , 19, 940-8	17
1366	Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. 2013 , 31, 2540-7	313
1365	Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. 2013 , 31, 96-102	44
1364	Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction. 2013 , 18, 341-7	1
1363	How should we treat newly diagnosed multiple myeloma patients?. 2013 , 2013, 488-95	38
1362	Total cost comparison in relapsed/refractory multiple myeloma. 2013 , 16, 614-22	21
1361	Dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) is an effective salvage regimen for multiple myeloma refractory to novel agents. 2013 , 54, 1117-9	7
1360	Improved outcomes with novel agents and auto-SCT for multiple myeloma in African-American patients. 2013 , 48, 319-20	2
1359	Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. 2013 , 48, 1179-84	12

1358	Combination immune therapies to enhance anti-tumor responses by NK cells. 2013 , 4, 481	57
1357	Everolimus enhances the cytotoxicity of bendamustine in multiple myeloma cells through a network of pro-apoptotic and cell-cycle-progression regulatory proteins. 2013 , 45, 683-91	9
1356	Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. 2013 , 19, 6030-8	116
1355	Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure. 2013 , 5, e2013037	7
1354	Impact of pretransplant donor and recipient cytomegalovirus serostatus on outcome for multiple myeloma patients undergoing reduced intensity conditioning allogeneic stem cell transplantation. 2013 , 5, e2013026	11
1353	Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. 2013 , 27, 2357-65	116
1352	Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist. 2013 , 4, 211-6	18
1351	The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. 2013 , 18, 27-36	47
1350	Efficient allocation of novel agents in multiple myeloma: a work in progress. 2013 , 18, 5-7	5
1349	Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. 2013 , 18, 37-45	53
1348	Kidney disease and multiple myeloma. 2013 , 8, 2007-17	93
1347	The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. 2013 , 161, 367-72	28
1346	Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. 2013 , 161, 499-507	17
1345	Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. 2013 , 162, 474-82	32
1344	Successful use of cyclophosphamide as an add-on therapy for multiple myeloma patients with acquired resistance to bortezomib or lenalidomide. 2013 , 2013, 651902	2
1343	Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. 2013 , 7, 53-73	19
1342	Cap dependent translation contributes to resistance of myeloma cells to bortezomib. 2013 , 1, e27245	3
1341	Cyclin D1 expression in multiple myeloma by immunohistochemistry: Case series of 14 patients and literature review. 2013 , 34, 283-91	9

1340	Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Mylbme 2009-02. <i>Blood</i> , 2013 , 121, 1968-75	2.2	173
1339	Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. 2013 , 162, 202-9		27
1338	Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. 2013 , 31, 448-55		211
1337	Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. 2013 , 119, 4188-95		34
1336	Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: a retrospective study at a single New Zealand centre. 2013 , 43, 130-7		2
1335	Renal transplant in plasma cell dyscrasias with lenalidomide treatment after autologous stem cell transplantation. 2013 , 18, 641-3		13
1334	Targeting the BRAF V600E mutation in multiple myeloma. 2013 , 3, 862-9		176
1333	Current therapeutic strategy for multiple myeloma. 2013 , 43, 116-24		28
1332	Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. <i>Blood</i> , 2013 , 121, 1961-7	2.2	132
1331	D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. 2013 , 161, 802-10		37
1330	Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients. 2013 , 3, e150		5
1329	Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?. 2013 , 27, 226-32		81
1328	Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. 2013 , 27, 2062-6		26
1327	Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. 2013 , 27, 695-701		27
1326	Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. 2013 , 3, e162		52
1325	Pursuing the curative blueprint for early myeloma. <i>Blood</i> , 2013 , 122, 486-90	2.2	14
1324	Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. 2013 , 3, e121		48
1323	Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation. 2013 , 2, S21-7		7

1322	Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal. 2013 , 27, 2269-71		2
1321	Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. 2013 , 31, 1984-9		75
1320	Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. <i>Blood</i> , 2013 , 122, 2799-806	2.2	70
1319	"IM ID"early treating multiple myeloma. <i>Blood</i> , 2013 , 121, 1926-8	2.2	4
1318	Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. <i>Blood</i> , 2013 , 122, 1376-83	2.2	66
1317	Intracellular NAD ⁺ depletion enhances bortezomib-induced anti-myeloma activity. <i>Blood</i> , 2013 , 122, 1243-55	2.2	65
1316	Pomalidomide. <i>Blood</i> , 2013 , 122, 2305-9	2.2	56
1315	Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. <i>Blood</i> , 2013 , 122, 3122-8	2.2	119
1314	Epidemiology of myeloma. 1-10		
1313	Treatment of relapsed/refractory myeloma. 144-166		
1312	Cost of Illness in Patients with Multiple Myeloma in Italy: The CoMiM Study. 2013 , 99, e193-e202		11
1311	Traitement du myélome multiple. 2013 , 8, 1-16		
1310	Autologous hematopoietic stem cell transplantation and maintenance therapy for multiple myeloma. 2013 , 2, 71-83		3
1309	Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells. 2013 , 43, 1809-16		38
1308	Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. 2013 , 11, 35-42		13
1307	Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece. 2013 , 5, 37-48		14
1306	Therapeutic decision making in hematopoietic SCT for multiple myeloma. 122-132		
1305	Strategies for the Treatment of Multiple Myeloma in 2013: Moving Toward the Cure. 2013 ,		

1304	The morphology of myeloma cells changes with progression of the disease. 2013 , 17, 272-5	2
1303	Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma. 2013 , 41	
1302	Impact of genetic abnormalities on the prognoses and clinical parameters of patients with multiple myeloma. 2013 , 33, 248-54	17
1301	Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. 2013 , 8, e70430	64
1300	The systemic cytokine environment is permanently altered in multiple myeloma. 2013 , 8, e58504	31
1299	Induction of malignant plasma cell proliferation by eosinophils. 2013 , 8, e70554	21
1298	Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. 2013 , 20, e13-20	17
1297	Multiple myeloma and kidney disease. 2013 , 2013, 487285	14
1296	Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma. 2013 ,	
1295	Multiple myeloma: an update. 2013 , 28, 3-11	24
1294	Multiple myeloma. 799-808	
1293	Induction Therapy in Multiple Myeloma. 2013 ,	
1292	Novel Approaches to Treatment of Double-Refractory Multiple Myeloma. 2013 , e302-e306	2
1291	New Tools for Diagnosis and Monitoring of Multiple Myeloma. 2013 , e313-e318	3
1290	Salvage therapy of multiple myeloma: the new generation drugs. 2014 , 2014, 456037	16
1289	Clinical outcome of bortezomib retreatment in patients with relapsed or refractory multiple myeloma. 2014 , 2014, 145843	7
1288	Novel agents in CNS myeloma treatment. 2014 , 14, 23-7	20
1287	Peripheral Blood Progenitor Cells Mobilization in Patients with Multiple Myeloma. 2014 , 04,	

1286	Potential role of daratumumab in the treatment of multiple myeloma. 2014 , 7, 1095-100	12
1285	Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. 2014 , 6, 87-96	25
1284	Practical guide on the use of second-line treatment in multiple myeloma. 2014 , 20, 208-225	
1283	Multiple myeloma: optimal management and long-term disease control. 2014 , 121	
1282	. 2014 ,	2
1281	Treatment of multiple myeloma in Akita: features and outcomes in the era of novel agents. 2014 , 54, 89-93	2
1280	Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. 2014 , 74, 4458-69	50
1279	Best treatment strategies in high-risk multiple myeloma: navigating a gray area. 2014 , 32, 2125-32	20
1278	The emerging role of carfilzomib combination therapy in the management of multiple myeloma. 2014 , 7, 265-90	19
1277	Myeloma relapse involving the heart and presenting as acute cardiac failure. 2014 , 32, e67-8	2
1276	Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens. 2014 , 100, 473-7	15
1275	Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. 2014 , 28, 2060-5	83
1274	Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies. 2014 , 28, 444-7	52
1273	Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. 2014 , 64, 422-44	61
1272	Association of response endpoints with survival outcomes in multiple myeloma. 2014 , 28, 258-68	107
1271	Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. 2014 , 28, 1529-36	54
1270	Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer. 2014 , 53, 547-56	1
1269	Plasmablastic myeloma presenting as rapidly progressive renal failure in a young adult. 2014 , 24, 41-4	9

1268	p53 abnormalities and potential therapeutic targeting in multiple myeloma. 2014 , 2014, 717919	28
1267	Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. 2014 , 5, 257	26
1266	Short-course bortezomib-based retreatment for patients with multiple myeloma who had received bortezomib-thalidomide-dexamethasone (VTD) as an initial therapy: A single-center case series. 2014 , 7, 977-981	3
1265	A practical approach to relapsed multiple myeloma. 2014 , 2014, 262-7	6
1264	Autologous stem cell transplantation in elderly patients with multiple myeloma: past, present, and future. 2014 , 2014, 394792	11
1263	Carfilzomib in multiple myeloma. 2014 , 14, 1685-99	13
1262	Targeted therapy for HM1.24 (CD317) on multiple myeloma cells. 2014 , 2014, 965384	10
1261	Membranous nephropathy superimposed on Churg-Strauss syndrome. 2014 , 24, 57-9	3
1260	Pomalidomide for multiple myeloma. 2014 , 7, 719-31	10
1259	The growing link between multiple myeloma and myeloid derived suppressor cells. 2014 , 55, 2681-2	6
1258	Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups. 2014 , 55, 2850-7	11
1257	Bortezomib-based combination regimens in myeloma: more is not necessarily better. 2014 , 55, 1439-40	
1256	Optimal management of elderly patients with myeloma. 2014 , 14, 217-28	5
1255	How long can we let the myeloma smolder?. 2014 , 7, 17-9	3
1254	Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma. 2014 , 74, 7418-29	24
1253	Multiple myeloma in the very old: an IASIA conference report. 2014 , 106,	14
1252	IMWG consensus on risk stratification in multiple myeloma. 2014 , 28, 269-77	387
1251	The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma. 2014 , 167, 194-206	15

1250	AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia. 2014 , 164, 352-365	24
1249	Future agents and treatment directions in multiple myeloma. 2014 , 7, 127-41	25
1248	Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. 2014 , 89, 302-5	2
1247	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. 2014 , 15, 1503-1512	207
1246	Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. 2014 , 16, 11-27	8
1245	United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma. 2014 , 36, 20-8	7
1244	Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma--response to Murphy et al. 2014 , 165, 892	1
1243	Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population. 2014 , 164, 684-93	33
1242	Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. 2014 , 89, 751-6	60
1241	Novel drug combinations for the management of relapsed/refractory multiple myeloma. 2014 , 14 Suppl, S71-7	11
1240	Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study. 2014 , 1, e112-9	8
1239	United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma. 2014 , 36, 665-75	1
1238	Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. 2014 , 166, 401-9	30
1237	The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. 2014 , 5, 197-210	18
1236	Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism. 2014 , 46, 597-604	17
1235	Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score. 2014 , 55, 2277-83	4
1234	Pomalidomide in the treatment of multiple myeloma and perspectives in other hematological malignancies. 2014 , 3, 223-231	
1233	AKT as a therapeutic target in multiple myeloma. 2014 , 18, 897-915	32

1232	A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. 2014 , 74, 1179-89	40
1231	Overcoming Bortezomib Resistance: A Review of the Second-Generation Proteasome Inhibitor Carfilzomib in the Treatment of Multiple Myeloma. 2014 , 81-98	
1230	Profile of elotuzumab and its potential in the treatment of multiple myeloma. 2014 , 2014, 15-27	22
1229	Serum growth differentiation factor 15 levels in newly diagnosed multiple myeloma patients. 2014 , 131, 173-8	9
1228	Therapeutic advancements in multiple myeloma. 2014 , 4, 241	40
1227	The impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myeloma. 2014 , 2014, 413149	12
1226	Expression of CD99 in Multiple Myeloma: A Clinicopathologic and Immunohistochemical Study of 170 Cases. 2014 , 48, 209-16	8
1225	Early application of percutaneous vertebroplasty reduces pain without affecting peripheral blood stem cell (PBSC) collection and transplant in newly diagnosed multiple myeloma (MM) patients. 2014 , 23, 773-8	6
1224	Positive correlation between baseline PET or PET/CT findings and clinical parameters in multiple myeloma patients. 2014 , 131, 193-9	18
1223	Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network. 2014 , 132, 211-9	43
1222	The work of living with a rare cancer: multiple myeloma. 2014 , 70, 2800-9	22
1221	Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. 2014 , 38, 517-24	12
1220	Lenalidomide and second malignancies in myeloma patients. 2014 , 15, 253-4	10
1219	POMALIDOMID łowy immunomodulujdy lek w terapii szpiczaka plazmocytoowego. 2014 , 45, 171-178	
1218	Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. 2014 , 28, 373-83	87
1217	Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes. 2014 , 93, 123-8	12
1216	Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. 2014 , 22, 417-26	74
1215	Current strategies for treatment of relapsed/refractory multiple myeloma. 2014 , 7, 97-111	58

1214	Expression of cereblon protein assessed by immunohistochemical staining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. 2014 , 93, 1371-80		44
1213	Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents. 2014 , 99, 441-9		11
1212	New approaches to management of multiple myeloma. 2014 , 15, 157-70		17
1211	A phase I trial of flavopiridol in relapsed multiple myeloma. 2014 , 73, 249-57		27
1210	Characteristics of unexpected protein bands in multiple myeloma patients after autologous stem cell transplantation. 2014 , 47, 588-92		2
1209	Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma. 2014 , 14, 389-94		12
1208	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. <i>Blood</i> , 2014 , 123, 1461-9	2.2	152
1207	Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. 2014 , 89, 355-62		17
1206	Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro. 2014 , 42, 274-81		17
1205	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. 2014 , 15, 333-42		206
1204	Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. 2014 , 166, 702-10		35
1203	Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. 2014 , 99, 361-71		81
1202	Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. 2014 , 28, 1122-8		880
1201	The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. 2014 , 55, 337-41		12
1200	The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. 2014 , 55, 11-8		4
1199	Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma. 2014 , 49, 223-7		23
1198	Multiple Myeloma. 2014 ,		9
1197	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). 2014 , 28, 525-42		179

1196	Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice. 2014 , 20, 804-13	23
1195	Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. 2014 , 23, 1193-209	6
1194	Long-term survival in multiple myeloma. 2014 , 2, 173-9	10
1193	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. 2014 , 92, 485-90	21
1192	Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. 2014 , 93, 407-13	13
1191	Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. 2014 , 4, e239	39
1190	Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. 2014 , 89, 999-1009	123
1189	Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials. 2014 , 38, 1048-54	13
1188	Initial treatment of transplant-ineligible patients in multiple myeloma. 2014 , 7, 67-77	8
1187	Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. 2014 , 18, 947-61	112
1186	Impact of Energy Balance on Cancer Disparities. 2014 ,	
1185	Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. 2014 , 14, 1127-44	12
1184	Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia. 2014 , 14, e169-72	9
1183	Advances in multiple myeloma therapy during two past decades. 2014 , 10, 38-40	14
1182	Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. 2014 , 14, 356-69	6
1181	Rapid detection of MYD88-L265P mutation by PCR-RFLP in B-cell lymphoproliferative disorders. 2014 , 28, 447-9	13
1180	Resistance to Proteasome Inhibitors in Cancer. 2014 ,	2
1179	Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review. 2014 , 92, 181-8	10

1178 Haematological Malignancy Outside Intensive Care. **2014**, 157-164

1177 Multiple myeloma in the older adult: better prospects, more challenges. **2014**, 32, 2531-40 47

1176 Quantification of clonal circulating plasma cells in relapsed multiple myeloma. **2014**, 167, 500-5 62

1175 European perspective on multiple myeloma treatment strategies in 2014. **2014**, 19, 829-44 77

1174 Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. **2014**, 89, E116-20 17

1173 Multiple Myeloma in Older Adults. **2014**, 3, 200-208 1

1172 Controversies in multiple myeloma: to transplant or not?. **2014**, 9, 360-7 2

1171 Maintenance therapy for multiple myeloma. **2014**, 28, 839-59 14

1170 A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. **2014**, 93, 89-98 31

1169 Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. **2014**, 93, 1571-7 3

1168 Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. **2014**, 140, 1947-56 25

1167 Holistic needs assessment in advanced, intensively treated multiple myeloma patients. **2014**, 22, 2615-20 23

1166 Therapie des multiplen Myeloms. **2014**, 17, 24-29

1165 Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection. **2014**, 28, 75-86 42

1164 Issues of front-line therapy for multiple myeloma--the standard of care. **2014**, 55, 1959-61 1

1163 Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. **2014**, 15, 1195-206 604

1162 Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. **2014**, 167, 563-5 29

1161 Five myths about cancer care in America. **2014**, 33, 1801-4 7

1160	Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer. 2014 , 11, 1939-54	70
1159	Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?. 2014 , 17, 245-53	7
1158	High-risk myeloma: when to transplant-or not. 2014 , 41, e1-9	
1157	[New drugs in the treatment of multiple myeloma]. 2014 , 143, 268-74	
1156	Nawrotowa postać szpiczaka plazmocytoowego leczona doustnie lenalidomidem w monoterapii łpis przypadku. 2014 , 45, 89-92	
1155	Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. 2014 , 14, 131-139.e1	39
1154	Improved long-term survival in multiple myeloma up to the age of 80 years. 2014 , 28, 1346-8	99
1153	Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma. 2014 , 49, 761-6	12
1152	MRI features of extramedullary myeloma. 2014 , 202, 803-10	23
1151	Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. 2014 , 25, 195-200	102
1150	Emerging therapies targeting the ubiquitin proteasome system in cancer. 2014 , 124, 6-12	93
1149	Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers. 2014 , 99, 408-16	44
1148	[Programs for continuing medical education: B session 7. Progress in treatment for hematologic diseases]. 2014 , 103, 717-23	
1147	The Tao of myeloma. <i>Blood</i> , 2014 , 124, 1873-9	2.2 42
1146	Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. <i>Blood</i> , 2014 , 123, 632-9	2.2 81
1145	CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. <i>Blood</i> , 2014 , 123, 3770-9	2.2 60
1144	Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. <i>Blood</i> , 2014 , 124, 1047-55	2.2 169
1143	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. <i>Blood</i> , 2014 , 123, 3073-9	2.2 306

1142	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. <i>Blood</i> , 2014 , 124, 907-12	2.2	83
1141	Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. <i>Blood</i> , 2014 , 124, 3748-57	2.2	400
1140	Pomalidomide for the treatment of relapsed and refractory multiple myeloma. 2014 , 2, 1089-1108		
1139	Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma. 2014 , 87, 224-31		10
1138	ShRNA-mediated Bmi-1 silencing sensitizes multiple myeloma cells to bortezomib. 2014 , 34, 616-23		10
1137	Myeloma and other paraproteinaemias. 2014 , 545-559		
1136	Glutaraldehyde fixation method for single-cell lipid analysis by time-of-flight secondary ion-mass spectrometry. 2014 , 46, 185-188		8
1135	Maintenance therapy for multiple myeloma after an autologous transplant: what have we learned?. 2014 , 3, 1-3		
1134	Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis. 2014 , 15 Suppl 11, S9		3
1133	Light Chain Escape Multiple Myeloma Complicated with Catastrophic Extramedullary Plasmacytoma Following Novel Agent Treatment. 2014 , 1, 39-45		
1132	Partial remission of acute myeloid leukemia complicating multiple myeloma following COAP chemotherapy: A case report. 2015 , 9, 1303-1306		0
1131	Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. 2015 , 4, 64-9		10
1130	Pathologic sternal involvement is a potential risk factor for severe sagittal plane deformity in multiple myeloma with concomitant thoracic fractures. 2015 , 15, 2503-8		3
1129	Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma. 2015 , 94, e2305		31
1128	Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma. 2015 , 55, 275-83		31
1127	Bendamustine in multiple myeloma. 2015 , 95, 377-88		16
1126	First characterization of platelet secretion defect in patients with familial hemophagocytic lymphohistiocytosis type 3 (FHL-3). <i>Blood</i> , 2015 , 125, 412-4	2.2	14
1125	Future distribution of multiple myeloma in the United States by sex, age, and race/ethnicity. <i>Blood</i> , 2015 , 125, 410-2	2.2	30

1124	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015 , 125, 2068-74	2.2	426
1123	How I treat fragile myeloma patients. <i>Blood</i> , 2015 , 126, 2179-85	2.2	57
1122	Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma. 2015 , 54, 1711-5		2
1121	Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. 2015 , 3, 47-68		11
1120	Analiza leczenia nawrotowych i opornych postaci szpiczaka plazmocytoowego w 111d polskich pacjentów. 2015 , 46, 385-392		
1119	Solitary ovarian plasmacytoma. A case report and review of literature. 2015 , 13, 20-2		2
1118	High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. 2015 , 8, 77		21
1117	Comparison of SPE, IFE, and FLC in Monitoring Patients with Multiple Myeloma After Autologous Stem Cell Transplantation. 2015 , 73, 643-7		2
1116	The characterization of adrenal insufficiency and identification of its risk factors in patients with plasma cell dyscrasias. 2015 , 90, E202-3		3
1115	Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. 2015 , 90, 1106-10		14
1114	A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial. 2015 , 5, 11		10
1113	Allogeneic stem cell transplantation for multiple myeloma. 2015 , 4, 1-8		
1112	Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma. 2015 , 26, 1078-82		8
1111	Cutaneous rash and dapson-induced hypersensitivity syndrome a common manifestation in adult immune thrombocytopenia. Presentation and outcome in 16 cases. 2015 , 90, E201-2		8
1110	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. 2015 , 90, 888-91		14
1109	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. 2015 , 90, 981-5		28
1108	Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. 2015 , 128, 1215-22		13
1107	Berleben 65- bis 70-jähriger Patienten mit Multiplem Myelom im Zeitalter von neuen Wirkstoffen und autologer Stammzell-Transplantation - Eine multizentrische, retrospektive, kollaborative Studie der Japanese Society of Myeloma und des European Myeloma Network. 2015 , 2, 18-19		

- 1106 Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. **2015**, 6, 41228-36 140
- 1105 Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients. **2015**, 8, 1277-84
- 1104 THE EFFICACY OF COMBINATION THERAPY WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF RELAPSED MULTIPLE MYELOMA. **2015**, 2, 50-54
- 1103 Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. **2015**, 6, 10460-72 53
- 1102 THE PRESENCE OF INTERFERING ANTIBODIES IN SELECTED CONTROL SERA ON THE EXAMPLE OF A SET FOR DETERMINATION OF IPSA. **2015**, 2, 55-57
- 1101 Bioinformatics analyses of differentially expressed genes associated with bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. **2015**, 8, 2681-8 9
- 1100 The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation. **2015**, 56, 1638-42 16
- 1099 Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. **2015**, 10, e0123866 30
- 1098 Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study. **2015**, 10, e0137552 7
- 1097 Combination of a Selective HSP90 α Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. **2015**, 10, e0143847 16
- 1096 NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma. **2015**, 2015, 178698 50
- 1095 Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. **2015**, 2015, 341430 34
- 1094 Un nouvel anticorps monoclonal le daratumumab en monothérapie dans le traitement du myélome multiple réfractaire ou en rechute. **2015**, 21, 260-261
- 1093 Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma. **2015**, 6, 15410-24 64
- 1092 Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma. **2015**, 29, 207-17 39
- 1091 Recent advances in the field of anti-cancer immunotherapy. **2015**, 3, 280-8 54
- 1090 When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response. **2015**, 13, 1163-73 34
- 1089 Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. **2015**, 5, e296 73

1088	The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma. 2015 , 107,	26
1087	Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy. 2015 , 15, 787-804	5
1086	A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. 2015 , 21, 4055-61	126
1085	Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma. 2015 , 29, 1918-27	38
1084	Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. 2015 , 33, 3921-9	109
1083	Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma. 2015 , 4, 1-11	9
1082	Clinical use of proteasome inhibitors in the treatment of multiple myeloma. 2014 , 8, 1-20	53
1081	Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. 2015 , 5, e349	45
1080	Targeting ubiquitination for cancer therapies. 2015 , 7, 2333-50	50
1079	Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy. 2015 , 5, e373	28
1078	Role of chemokine CX3CL1 in progression of multiple myeloma via CX3CR1 in bone microenvironments. 2015 , 33, 2935-9	10
1077	Bortezomib-containing regimens are effective in multiple myeloma--results of a non-interventional phase IV study. 2015 , 38, 167-73	5
1076	Panobinostat: a review of trial results and future prospects in multiple myeloma. 2015 , 8, 9-18	26
1075	The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors. 2015 , 25, 834-40	22
1074	Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center. 2015 , 94, 97-105	8
1073	The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit. 2015 , 90, E86-91	6
1072	Novel agents have a significant impact on survival of patients with multiple myeloma. 2015 , 127, 92-7	3
1071	Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era. 2015 , 106, 179-85	14

1070	Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study. 2015 , 15, 103-9	14
1069	Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. 2015 , 15, 110-4	27
1068	Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement. 2015 , 119, 186-94	6
1067	The use of novel agents in multiple myeloma patients with hepatic impairment. 2015 , 11, 501-10	11
1066	In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. 2015 , 29, 705-14	50
1065	Managing multiple myeloma in the over 70s: a review. 2015 , 80, 148-54	6
1064	Recent cancer survival in Germany: an analysis of common and less common cancers. 2015 , 136, 2649-58	54
1063	Treatment-related symptom management in patients with multiple myeloma: a review. 2015 , 23, 1431-45	27
1062	Panobinostat for the treatment of multiple myeloma. 2015 , 3, 229-238	2
1061	Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation. 2015 , 21, 1291-8	8
1060	Treatment of myeloma patients with renal impairment. 2015 , 8, 30-34	0
1059	PSMB4 promotes multiple myeloma cell growth by activating NF- κ B-miR-21 signaling. 2015 , 458, 328-33	23
1058	Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma. 2015 , 50, 511-6	6
1057	Relationship of P-selectin glycoprotein ligand-1 to prognosis in patients with multiple myeloma. 2015 , 15, 164-70	4
1056	Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation. 2015 , 15, 17	40
1055	Current and future immunotherapeutic approaches to multiple myeloma therapy. 2015 , 4, 23-31	
1054	Promising therapies in multiple myeloma. <i>Blood</i> , 2015 , 126, 300-10	2.2 71
1053	Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma. 2015 , 8, 481-91	24

1052	Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database. 2015 , 21, 1823-9	26
1051	Single-molecule analysis reveals widespread structural variation in multiple myeloma. 2015 , 112, 7689-94	35
1050	Ixazomib for the treatment of multiple myeloma. 2015 , 24, 1287-98	33
1049	Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients. 2015 , 121, 853-62	1
1048	Management of Elderly Patients with Plasma Cell Myeloma. 2015 , 32, 427-42	1
1047	Novel therapeutic strategies for multiple myeloma. 2015 , 43, 732-41	79
1046	Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations. 2015 , 8, 355-66	18
1045	A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. 2015 , 23, 1503-12	22
1044	Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma. 2015 , 101, 37-45	8
1043	Long-term disease control by pomalidomide-/dexamethasone-based therapy in a patient with advanced multiple myeloma: a case report and review of the literature. 2015 , 8, 189-95	8
1042	Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. 2015 , 64, 1021-32	21
1041	Prognostic effect of comorbidity indices in elderly patients with multiple myeloma. 2015 , 15, 416-9	22
1040	Recent advances in multiple myeloma. 2015 , 20, 411-2	3
1039	The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents. 2015 , 75, 367-75	3
1038	Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time. 2015 , 21, 1530-6	102
1037	Plasmapheresis in cast nephropathy: yes or no?. 2015 , 24, 177-82	6
1036	Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development. 2015 , 6, 120-7	33
1035	Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. 2015 , 29, 689-95	68

1034	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. 2015 , 11, 1153-68	23
1033	Current therapeutic strategies for multiple myeloma. 2015 , 20, 423-30	20
1032	A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. 2015 , 121, 3622-30	25
1031	Outcome in Multiple Myeloma Patients Eligible for Stem Cell Transplantation: A Single-Center Experience. 2015 , 89, 196-204	3
1030	Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma. 2015 , 56, 415-9	7
1029	Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. 2015 , 56, 407-14	7
1028	An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma. 2015 , 168, 148-51	3
1027	[Pomalidomide for multiple myeloma]. 2015 , 36, 613-8	0
1026	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. 2015 , 169, 843-50	42
1025	Pulmonary hypertension complicating multiple myeloma. 2015 , 5, 590-7	12
1024	Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. 2015 , 100, e289-91	10
1023	Disease-proportional proteasomal degradation of missense dystrophins. 2015 , 112, 12414-9	15
1022	Clinical characteristics of patients with relapsed multiple myeloma. 2015 , 41, 827-35	26
1021	Novel Induction Regimens in Multiple Myeloma. 2015 , 10, 388-94	1
1020	Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution. 2015 , 39, 693-9	17
1019	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. 2015 , 373, 1207-19	761
1018	Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma. 2015 , 11, 2121-36	9
1017	Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines. 2015 , 355, 168-73	29

1016	A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents. 2015 , 94, 145-51	11
1015	Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide. 2015 , 56, 2388-91	1
1014	Multiple myeloma. 2015 , 385, 2197-208	401
1013	Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. 2015 , 356, 443-53	41
1012	Treatment of patients with multiple myeloma over 65 yr: more tolerability or better response?. 2015 , 94, 424-30	5
1011	Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. 2015 , 50, 209-15	96
1010	Targeting the bone marrow microenvironment in multiple myeloma. 2015 , 263, 160-72	223
1009	Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. 2015 , 372, 142-52	928
1008	Multiple myeloma after kidney transplantation. 2015 , 29, 76-84	12
1007	Current treatment landscape for relapsed and/or refractory multiple myeloma. 2015 , 12, 42-54	146
1006	Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma. 2015 , 94, 445-52	23
1005	Management of Hematological Cancer in Older People. 2015 ,	
1004	Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. 2015 , 94, 643-9	11
1003	Optimizing the treatment of patients with multiple myeloma and renal impairment. 2015 , 15, 187-98	17
1002	Efficacy and Safety of Bortezomib in Multiple Myeloma Patients with Hepatitis B: A Multicenter Retrospective Study. 2016 , 129, 274-8	2
1001	49 Tumors of the Thoracolumbar Spine. 2016 ,	
1000	Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma. 2016 ,	78
999	Maintenance Therapy in Multiple Myeloma: Novel Concepts in Clinical Practice from Recent Clinical Trials. 2016 , 11, 124-7	

998	A rare case of diffuse large B cell lymphoma-associated hemophagocytic syndrome initially present in the bone marrow with a favorable clinical course. 2016 , 51, 144-7	2
997	Bilateral myelomatous pleural effusion: presentation of two cases. 2016 , 51, 142-4	1
996	Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes. 2016 , 6, 21-35	0
995	The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches. 2016 , 56, 20-7	6
994	Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. 2016 , 51, 193-199	3
993	Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma. 2016 , 4,	3
992	More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis. 2016 , 10, 3673-3679	5
991	Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical Methodologies. 2016 , 4,	6
990	Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy. 2016 , 35, 210-21	6
989	Risk stratification, treatment selection, and transplant eligibility in multiple myeloma: a qualitative study of the perspectives and self-reported practices of oncologists. 2016 , 23, e598-e604	1
988	Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare. 2016 , 2016, 3645623	2
987	Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis. 2016 , 2016, 6848902	14
986	MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment. 2016 , 2016, 6504593	42
985	Development of Novel Immunotherapies for Multiple Myeloma. 2016 , 17,	18
984	Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. 2016 , 8, 35-44	21
983	Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide. 2016 , 49, e5128	1
982	Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. 2016 , 17,	43
981	Increasing Disadvantages in Cancer Survival in New Zealand Compared to Australia, between 2000-05 and 2006-10. 2016 , 11, e0150734	9

980	Multiple myeloma in the very elderly patient: challenges and solutions. 2016 , 11, 423-35	23
979	VII. Hematopoietic Stem Cell Transplantation for Multiple Myeloma. 2016 , 105, 1246-1254	
978	'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors. 2016 , 97, 25-32	58
977	Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. 2016 , 95, 1645-51	4
976	The Prognostic Significance of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Patients With Multiple Myeloma. 2016 , 30, 1208-1213	17
975	The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. 2016 , 16, 427	64
974	Novel agents in the treatment of multiple myeloma: a review about the future. 2016 , 9, 52	116
973	Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. 2016 , 9, 51	73
972	Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function. 2016 , 34, 200-207	5
971	Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy. 2016 , 239, 262-73	22
970	Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. 2016 , 174, 911-22	84
969	Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients. 2016 , 91, 700-4	21
968	High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. 2016 , 82, 149-59	33
967	A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma. 2016 , 173, 70-81	18
966	Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. 2016 , 3, e572-e580	29
965	Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice. 2016 , 3, 16032	23
964	Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. 2016 , 6, e506	49
963	The relationship between spinopelvic measurements and patient-reported outcome scores in patients with multiple myeloma of the spine. 2016 , 98-B, 1234-9	1

962	Advances and practical use of monoclonal antibodies in multiple myeloma therapy. 2016 , 2016, 512-520	4
961	Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies. 2016 , 95, e5202	7
960	Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells. 2016 , 16, 203-12	21
959	Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. 2016 , 22, 1391-1396	24
958	Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. 2016 , 30, 2208-2213	55
957	Nuances in the Management of Older People With Multiple Myeloma. 2016 , 11, 241-51	11
956	Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab. 2016 , 50, 555-68	18
955	Myeloma of the central nervous system - an ongoing conundrum!. 2016 , 57, 1505-6	2
954	Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence. 2016 , 17, 723-6	1
953	Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. 2016 , 104, 300-9	43
952	Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. 2016 , 30, 2047-2054	48
951	A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples. 2016 , 24, 695-702	13
950	Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies. 2016 , 12, 705-11	2
949	How I treat extramedullary myeloma. <i>Blood</i> , 2016 , 127, 971-6	2.2 103
948	Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. <i>Blood</i> , 2016 , 128, 384-94	2.2 499
947	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. <i>Blood</i> , 2016 , 128, 37-44	2.2 272
946	Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review. 2016 , 11, 2255-2260	11
945	Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. 2016 , 7, 187-95	38

944	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , 2016 , 127, 713-21	2.2	99
943	[Predictive molecular pathological stratification of hematological neoplasms]. 2016 , 37, 210-216		
942	Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders. 2016 , 16, 684-692.e3		11
941	Plasmocytomes intraduraux extraméullaires. 2016 , 7, 209-212		
940	Myelomatous Involvement of the Central Nervous System. 2016 , 16, 644-654		29
939	The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. 2016 , 33, 1896-1920		11
938	Plasma Cell Dyscrasias. 2016 ,		1
937	Treatment of Relapsed/Refractory Multiple Myeloma. 2016 , 169, 169-194		6
936	A new ten-gene risk fraction model serving as prognostic indicator for clinical outcome of multiple myeloma. 2016 , 37, 15967		1
935	V8 induces apoptosis and the endoplasmic reticulum stress response in human multiple myeloma RPMI 8226 cells via the PERK-eIF2 β -ATF4 signaling pathway. 2016 , 12, 2702-2709		2
934	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. 2016 , 375, 1319-1331		930
933	Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. 2016 , 169, 145-167		6
932	A retrospective analysis to examine factors associated with mortality in Medicare beneficiaries newly diagnosed with multiple myeloma. 2016 , 32, 1989-1996		6
931	New investigational drugs with single-agent activity in multiple myeloma. 2016 , 6, e451		54
930	Hematopoietic Cell Transplantation for Multiple Myeloma. 2016 , 625-639		
929	How to Think About Risk in Myeloma. 2016 , 16 Suppl, S135-8		1
928	The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution. 2016 , 5, 500-5		5
927	Myeloma today: Disease definitions and treatment advances. 2016 , 91, 90-100		105

926	Life-threatening bowel perforation while on thalidomide-based triplet regimen for multiple myeloma: a retrospective case series. 2016 , 173, 786-8	2
925	Daratumumab in multiple myeloma: a guide to its use as monotherapy in the EU. 2016 , 32, 463-469	8
924	Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. 2016 , 6, e466	15
923	Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. 2016 , 101, 872-8	18
922	Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells. 2016 , 15, 3233-3242	19
921	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. 2016 , 91, 1129-1134	42
920	Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma. 2016 , 16, 610-615	12
919	IRE1 β BP1 signaling pathway, a potential therapeutic target in multiple myeloma. 2016 , 49, 7-12	36
918	Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. 2016 , 97, 416-429	62
917	Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. 2016 , 16, 1291-301	10
916	Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With \geq Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD. 2016 , 21, 1355-1361	73
915	A multicenter clinical study to determine the feasible initial dose of lenalidomide for maintenance therapy in patients with multiple myeloma following autologous peripheral blood stem-cell transplantation. 2016 , 4, 965-970	
914	Multiple myeloma detection based on blood plasma surface-enhanced Raman spectroscopy using a portable Raman spectrometer. 2016 , 13, 105601	5
913	Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. 2016 , 104, 281-92	37
912	A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment. 2016 , 135, 140-5	4
911	Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion. 2016 , 12, 921-6	20
910	A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. 2016 , 43, 682-689	39
909	Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma. <i>Blood</i> , 2016 , 128, 2241-2252	2.2 36

908	Multiple myeloma epidemiology and survival: A unique malignancy. 2016 , 43, 676-681	255
907	Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma. 2016 , 104, 596-604	9
906	Primary plasma cell leukemia 2.0: advances in biology and clinical management. 2016 , 9, 1063-1073	12
905	Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. 2016 , 16, 613	14
904	Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. 2016 , 3, e506-e515	98
903	Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells. 2016 , 14, 3469-75	10
902	Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma. 2016 , 4, 287-301	4
901	Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. 2016 , 16, 151	14
900	Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy. 2016 , 96, 417-24	1
899	Risk of skin cancer in multiple myeloma patients: a retrospective cohort study. 2016 , 97, 439-444	8
898	New synthesis route for the preparation of pomalidomide. 2016 , 46, 1343-1348	3
897	LC-MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients. 2016 , 1028, 111-119	21
896	Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma. 2016 , 9, 621-8	3
895	Management of high-risk Myeloma: an evidence-based review of treatment strategies. 2016 , 9, 753-65	2
894	Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices. 2016 , 9, 707-17	32
893	Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program. 2016 , 16, 46	1
892	Pomalidomide in the management of relapsed multiple myeloma. 2016 , 12, 1975-83	7
891	Core Concepts in Dialysis and Continuous Therapies. 2016 ,	2

890	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. 2016 , 57, 2833-2838	23
889	Improved survival of older patients with multiple myeloma in the era of novel agents. 2016 , 34, 217-223	17
888	An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). 2016 , 91, 806-11	7
887	Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. 2016 , 73, 1569-89	62
886	Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells. 2016 , 469, 236-42	7
885	Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis. 2016 , 11, 431-41	42
884	Trends in hematological cancer in the elderly in Denmark, 1980-2012. 2016 , 55 Suppl 1, 98-107	22
883	Biotargeting in Metastatic Bone Disease. 2016 , 131-142	
882	Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma. 2016 , 9, 315-23	4
881	Oral ixazomib maintenance therapy in multiple myeloma. 2016 , 16, 21-32	5
880	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. 2016 , 17, 27-38	576
879	Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma. 2016 , 73, 441-50	17
878	Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma. 2016 , 90, 40-6	17
877	Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. 2016 , 6, e401	21
876	USO1 promotes tumor progression via activating Erk pathway in multiple myeloma cells. 2016 , 78, 264-271	10
875	The role of tandem stem cell transplantation for multiple myeloma patients. 2016 , 16, 515-34	10
874	Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. 2016 , 57, 2058-64	9
873	Preclinical animal models of multiple myeloma. 2016 , 5, 772	27

872	Multiple Myeloma: Treatment is Getting Individualized. 2016 , 32, 3-9	4
871	A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity. 2016 , 14, 253-66	14
870	High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma. 2016 , 114, 463-8	37
869	[Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?]. 2016 , 37, 473-9	3
868	Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis. 2016 , 57, 2077-83	5
867	Practical Approaches to the Management of Dual Refractory Multiple Myeloma. 2016 , 11, 148-55	5
866	A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. 2016 , 30, 1320-6	30
865	Early mortality in multiple myeloma: Experiences from a single institution. 2016 , 21, 392-8	11
864	Accuracy of Bone Marrow Flow Cytometry Analysis in Patients With Plasma Cell Neoplasm in Thailand: A Single Institutional Study. 2016 , 16, e27-37	0
863	Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. 2016 , 6, e378	39
862	Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience. 2016 , 21, 280-6	6
861	Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates. 2016 , 30, 87-93	6
860	A single-center retrospective analysis of first-line therapy of multiple myeloma with bendamustine-bortezomib-dexamethasone. 2016 , 57, 2065-70	2
859	The Shreveport Myeloma Experience: Survival, Risk Factors and Other Malignancies in the Age of Stem Cell Transplantation. 2016 , 135, 146-55	7
858	Monocyte recovery at day 100 is associated with improved survival in multiple myeloma patients who undergo allogeneic hematopoietic cell transplantation. 2016 , 51, 297-9	6
857	Multiple Myeloma: Diagnosis and Treatment. 2016 , 91, 101-19	290
856	Allogeneic stem cell transplantation for multiple myeloma: is there a future?. 2016 , 51, 492-500	39
855	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. 2016 , 387, 1551-1560	581

854	Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation. 2016 , 51, 529-35	11
853	Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. 2016 , 30, 1005-17	159
852	Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF. 2016 , 57, 1389-97	4
851	mTOR Inhibition for Cancer Therapy: Past, Present and Future. 2016 ,	2
850	Changes in survival rate of multiple myeloma after the introduction of bortezomib: a single institutional experience over 20 years. 2016 , 95, 63-72	7
849	Upregulation of CCL2 via ATF3/c-Jun interaction mediated the Bortezomib-induced peripheral neuropathy. 2016 , 53, 96-104	33
848	Metastatic Bone Disease. 2016 ,	9
847	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. 2016 , 9, 35-48	19
846	Ixazomib: an oral proteasome inhibitor for the treatment of multiple myeloma. 2016 , 4, 105-113	3
845	Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. 2016 , 30, 526-35	67
844	ESRD due to Multiple Myeloma in the United States, 2001-2010. 2016 , 27, 1487-94	24
843	Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults. 2016 , 32, 191-205	3
842	Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. 2016 , 32, 95-103	59
841	Risk of multiple myeloma in a case-spouse study. 2016 , 57, 1450-9	4
840	Infectious complications in patients with newly diagnosed multiple myeloma: A complication from the past?. 2016 , 57, 258-268	5
839	Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma. 2016 , 57, 1677-86	19
838	A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. 2016 , 22, 1067-75	28
837	Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. 2016 , 30, 995-8	10

836	Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells. 2016 , 30, 104-11	36
835	The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. 2016 , 43, 58-66	40
834	Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma. 2016 , 34, 102-7	3
833	Expression of MAGE-C1/CT7 provides prognostic information in multiple myeloma. 2017 , 58, 244-246	1
832	Developments in the Field of Myeloma in the Last Decade. 2017 , 33, 3-7	2
831	Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. 2017 , 58, 1-15	10
830	Efficacy and safety of elotuzumab for the treatment of multiple myeloma. 2017 , 16, 237-245	4
829	Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study. 2017 , 17, 89-96.e3	29
828	Deacetylase inhibitors: an advance in myeloma therapy?. 2017 , 10, 229-237	24
827	Is immunotherapy here to stay in multiple myeloma?. 2017 , 102, 423-432	31
826	The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry. 2017 , 96, 653-663	6
825	Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line. 2017 , 55, 33-40	6
824	[Orbital apex syndrome revealing multiple myeloma]. 2017 , 46, 449-452	
823	Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma. 2017 , 98, 529-541	21
822	Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma. 2017 , 98, 569-576	3
821	Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone. 2017 , 102, 168-175	7
820	Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan. 2017 , 108, 461-468	13
819	Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis. 2017 , 137, 163-172	8

818	Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. 2017 , 8, 15086		77
817	The safety of daratumumab for the treatment of multiple myeloma. 2017 , 16, 753-760		4
816	Identification and expression of MMSA-8, and its clinical significance in multiple myeloma. 2017 , 37, 3235-3243		1
815	How is patient care for multiple myeloma advancing?. 2017 , 10, 551-561		9
814	Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison. 2017 , 92, E146-E152		18
813	A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. <i>Blood</i> , 2017 , 129, 3294-3303	2.2	125
812	Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. <i>Blood</i> , 2017 , 130, 1189-1197	2.2	140
811	Daratumumab for the treatment of multiple myeloma. 2017 , 17, 887-893		23
810	Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. 2017 , 98, 289-295		2
809	RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. 2017 , 31, 1706-1714		31
808	Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic. 2017 , 96, 441-448		3
807	Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. 2017 , 17, 424-432		10
806	Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). 2017 , 143, 2049-2058		6
805	Bortezomib-Induced Muscle Toxicity in Multiple Myeloma. 2017 , 76, 620-630		16
804	Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?. 2017 , 12, 309-316		14
803	Myeloma; living better and living longer - a look at the advances. 2017 , 2, 153-166		
802	Tumors of the Sacrum. 2017 ,		2
801	Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. 2017 , 15, 230-269		142

800	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. 2017 , 92, E507-E512	3
799	Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. 2017 , 18, 1061-1079	3
798	A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivo. 2017 , 486, 916-922	3
797	A systematic review of health-related quality of life in longitudinal studies of myeloma patients. 2017 , 99, 3-17	38
796	Posttransplant maintenance therapy in multiple myeloma: the changing landscape. 2017 , 7, e545	30
795	Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. 2017 , 31, 2426-2434	49
794	A family-centered intervention for the transition to living with multiple myeloma as a chronic illness: A pilot study. 2017 , 35, 86-89	5
793	In-Hospital Mortality and Post-Transplantation Complications in Elderly Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Population-Based Study. 2017 , 23, 1203-1207	20
792	Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex). 2017 , 57, 45-54	7
791	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. 2017 , 92, 578-598	88
790	Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. 2017 , 389, 519-527	496
789	Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. 2017 , 31, 1727-1734	35
788	Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. 2017 , 102, 785-795	73
787	Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. 2017 , 96, 449-459	14
786	Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment. 2017 , 56, 915-924	46
785	Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. <i>Blood</i> , 2017 , 129, 299-306	2.2 61
784	Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors. 2017 , 36, 585-598	7
783	Evolutionary biology of high-risk multiple myeloma. 2017 , 17, 543-556	119

782	Novel Immunotherapies for Multiple Myeloma. 2017 , 12, 344-357	27
781	Infectious complications in multiple myeloma receiving autologous stem cell transplantation in the past 10 years. 2017 , 106, 801-810	10
780	Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077). 2017 , 143, 2545-2553	8
779	Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience. 2017 , 93, 295-301	1
778	Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. 2017 , 8, 33-38	13
777	Myeloma and Bone Disease. 2017 , 15, 483-498	35
776	High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma. 2017 , 96, 2079-2088	6
775	Introduction. 2017 , 33, 223-224	
774	Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction. 2017 , 17, 513-519.e1	12
773	Identifying cancer drug regimens in French health insurance database: An application in multiple myeloma patients. 2017 , 26, 1492-1499	8
772	High-risk Multiple Myeloma: Definition and Management. 2017 , 17S, S80-S87	26
771	Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. 2017 , 102, 1767-1775	36
770	Elderly patients with multiple myeloma: towards a frailty approach?. 2017 , 29, 315-321	55
769	Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myeloma. 2017 , 10, 159-163	1
768	Identifying multiple myeloma patients using data from the French health insurance databases: Validation using a cancer registry. 2017 , 96, e6189	13
767	Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort. 2017 , 34, 153	6
766	Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. 2017 , 23, 6602-6615	19
765	Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome. 2017 , 52, 1473-1475	12

764	Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels. 2017 , 14, 3243-3248		8
763	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. 2017 , 92, 1146-1155		22
762	[Multiple Myeloma - Current Status in Diagnostic Testing and Therapy]. 2017 , 155, 575-586		16
761	Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis. 2017 , 6, 2876-2885		38
760	Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. 2017 , 17, 621-630		4
759	Construction of a recombinant lentivirus-mediated shRNA expression vector targeting the human PSMD10 gene and validation of RNAi efficiency in RPMI-8226 multiple myeloma cells. 2017 , 38, 809-818		4
758	Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies. 2017 , 22, 762-767		38
757	Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma. 2017 , 10, 632-640		15
756	Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients. 2017 , 8, 28-34		12
755	Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes. 2017 , 17, 575-583.e2		47
754	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017 , 130, 1198-1204	2.2	46
753	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. 2017 , 179, 66-74		12
752	Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union. 2017 , 12, 17		4
751	Living with Multiple Myeloma: A Continuum-Based Approach to Cancer Survivorship. 2017 , 33, 348-361		12
750	Down-regulation of long non-coding RNA MALAT1 by RNA interference inhibits proliferation and induces apoptosis in multiple myeloma. 2017 , 44, 1032-1041		23
749	Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014. 2017 , 31, 1998-2000		12
748	The possible role of burden of therapy on the risk of myeloma extramedullary spread. 2017 , 96, 73-80		18
747	Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma. 2017 , 101, 81-88		25

746	Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients. 2017 , 92, E15-E17	14
745	Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China. 2017 , 13, e408-e415	1
744	A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. 2017 , 176, 440-447	7
743	The effect of microenvironmental factors on the development of myeloma cells. 2017 , 35, 741-745	2
742	Radiation Therapy in Hematologic Malignancies. 2017 ,	
741	Plasma cell leukemia: update on biology and therapy. 2017 , 58, 1538-1547	26
740	The next generation of novel therapies for the management of relapsed multiple myeloma. 2017 , 13, 63-75	7
739	Race-based differences in routine cytogenetic profiles of patients with multiple myeloma. 2017 , 176, 322-324	2
738	Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data. 2017 , 15, 45-55	4
737	New Developments in the Bioarchaeology of Care. 2017 ,	17
736	A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). 2017 , 31, 107-114	81
735	Mummy Studies and the Soft Tissue Evidence of Care. 2017 , 199-218	3
734	Epidemiology of Hematologic Malignancies. 2017 , 543-569	7
733	The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care. 2017 , 23, 225-238	31
732	Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. 2017 , 58, 552-559	7
731	Practical Considerations in Managing Relapsed Multiple Myeloma. 2017 , 17, 69-77	7
730	Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs. 2017 , 105, 423-432	1
729	Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents. 2017 , 98, 269-279	17

728	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. 2017 ,	6
727	[Monoclonal gammopathy of undetermined significance and multiple myeloma]. 2017 , 76, 33-37	1
726	Extramedullary Solitary Plasmacytoma: Demonstrating the Role of F-FDG PET Imaging. 2017 , 11, XD01-XD03	7
725	Long-term stabilisation of myeloma with curcumin. 2017 , 2017,	5
724	CD86 regulates myeloma cell survival. 2017 , 1, 2307-2319	9
723	Carfilzomib boosted combination therapy for relapsed multiple myeloma. 2017 , 10, 895-907	13
722	Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. 2017 , 10,	29
721	Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review. 2017 , 2017, 6934183	5
720	Extraosseous Multiple Myeloma: Case Report of Presentation in the Lower Extremity Soft Tissues with Literature Review. 2017 , 2017, 9159035	7
719	Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials. 2017 , 9, 287-298	6
718	Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature. 2017 , 12, e0179406	5
717	Long-term effects and psychological adjustment: study protocol of a large register-based study on quality of life among survivors of hematological malignancies. 2017 , 17, 482	7
716	Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling. 2018 , 10, e2018014	11
715	High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma. 2017 , 8, 48350-48361	5
714	Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions. 2017 , 9, 189-196	8
713	STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma. 2017 , 52, 293-299	14
712	VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma. 2017 , 10, 217-226	5
711	Melphalan modifies the bone microenvironment by enhancing osteoclast formation. 2017 , 8, 68047-68058	8

710	Maintenance Lenalidomide After Transplantation in Multiple Myeloma Prolongs Survival-In Most. 2017 , 35, 3269-3271	3
709	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. 2017 , 35, 2900-2910	175
708	Antitumoral effect of arsenic compound, sodium metaarsenite (KML001), on multiple myeloma cells. 2017 , 51, 1739-1746	2
707	Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico. 2018 , 124, 1946-1953	12
706	Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. 2018 , 103, 890-897	35
705	Ixazomib in the management of relapsed multiple myeloma. 2018 , 14, 2013-2020	5
704	Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. 2018 , 32, 2427-2434	5
703	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. 2018 , 32, 1567-1574	31
702	Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014. 2018 , 32, 2054-2057	3
701	A novel approach for medical research on lymphomas: A study validation of claims-based algorithms to identify incident cases. 2018 , 97, e9418	7
700	Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. 2018 , 101, 237	54
699	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. 2018 , 24, 2127-2132	12
698	An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma. 2018 , 18, 400-407.e1	4
697	Efficacy and Survival Outcome Associated with the Use of Novel Agents and Autologous Stem Cell Transplantation in Cases of Immunoglobulin D Multiple Myeloma in Korea. 2018 , 139, 185-192	6
696	Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. 2018 , 97, 1453-1462	18
695	HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the Proteasome. 2018 , 92,	12
694	Multiple Myeloma. 2018 , 463-483	
693	Bone Disease. 2018 , 111-140	

692	Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States. 2018 , 18, 152-160	27
691	Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. 2018 , 24, 1372-1378	17
690	Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients. 2018 , 7, 831-841	12
689	Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft. 2018 , 36, 436-444	10
688	Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan. 2018 , 139, 35-44	5
687	Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies. 2018 , 17, 1326-1333	25
686	Platelets Enhance Multiple Myeloma Progression via IL-1 β Upregulation. 2018 , 24, 2430-2439	26
685	Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013. 2018 , 53, 105-110	16
684	Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. 2018 , 124, 1710-1721	24
683	The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. 2018 , 97, 839-849	6
682	Transfusion management for patients taking an anti-CD38 monoclonal antibody. 2018 , 40, 25-29	5
681	A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. 2018 , 121, 74-89	15
680	An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. <i>Blood</i> , 2018 , 131, 746-758	2.2 90
679	Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. 2018 , 7, 307-316	21
678	Triplet vs. doublet drug regimens for managing multiple myeloma. 2018 , 19, 137-149	16
677	Heavy/light chain assay as a biomarker for diagnosis and follow-up of multiple myeloma. 2018 , 479, 7-13	4
676	Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma. 2018 , 355, 350-356	1
675	Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. 2018 , 21, 450-467	10

674	Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro. 2018 , 39, 2873-2880	6
673	History of Multiple Myeloma. 2018 , 511-524	
672	The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma. 2018 , 15, 6094-6106	20
671	Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies. 2018 , 18, e219-e240	8
670	Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients with multiple myeloma awaiting autologous haematopoietic stem cell transplantation? Protocol for the PREeMPT study. 2018 , 8, e021333	9
669	Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving bortezomib-based therapy for multiple myeloma. 2018 , 22, 43-48	6
668	Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma. 2018 , 18, 210-218	15
667	Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy. 2018 , 11, 423-435	15
666	Evaluation of the Relevance of Surgery in Patients with Multiple Myeloma Harboring Symptomatic Spinal Involvement: A Retrospective Case Series. 2018 , 114, e356-e365	2
665	Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review. 2018 , 26, 2075-2090	15
664	Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways. 2018 , 18, 311-320	25
663	The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma. 2018 , 24, 1392-1398	9
662	Plasma cell diseases and organ transplant: A comprehensive review. 2018 , 18, 1046-1058	7
661	Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib. 2018 , 24, 281-289	1
660	Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer. 2018 , 59, 288-299	9
659	Natural history of t(11;14) multiple myeloma. 2018 , 32, 131-138	43
658	Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice. 2018 , 36, 210-216	6
657	The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. 2018 , 9, 138-144	18

656	Minimal residual disease in multiple myeloma: Benefits of flow cytometry. 2018 , 40, 12-20	5
655	A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma. 2018 , 14, 319-329	5
654	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. 2018 , 93, 179-186	29
653	Personalized Therapy for Multiple Myeloma. 2018 ,	1
652	Treat or palliate: outcomes of very elderly myeloma patients. 2018 , 103, e32-e34	10
651	Preclinical Development of CD38-Targeted [Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma. 2018 , 59, 216-222	37
650	Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain. 2018 , 57, 42-49.e1	1
649	Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. 2018 , 182, 176-192	54
648	A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple Myeloma. 2018 , 103, 67-76	8
647	Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma. 2018 , 18, e77-e84	7
646	Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. 2018 , 81, 183-193	11
645	Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. 2018 , 34, 775-783	6
644	Role of Plasmapheresis in the Management of Acute Kidney Injury in Patients With Multiple Myeloma: Should We Abandon It?. 2018 , 22, 79-86	8
643	Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience. 2018 , 18, e69-e75	5
642	CAR T cell therapy for multiple myeloma: where are we now and where are we headed?. 2018 , 59, 2056-2067	41
641	Treatment of Patients in First or Second Relapse. 2018 , 77-102	
640	Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma. 2018 , 97, 299-307	2
639	Economic burden of multiple myeloma among patients in successive lines of therapy in the United States. 2018 , 59, 941-949	21

638	Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study. 2018 , 100, 10-19	6
637	Treatment of Multiple Myeloma in Elderly Patients: A Review of Literature and Practice Guidelines. 2018 , 10, e3669	4
636	Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma. 2018 , 2,	18
635	Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies. 2018 , 2, 1-12	8
634	Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. 2018 , 36, 728-734	164
633	Incidence of spinal disease and role of spinal radiotherapy in multiple myeloma. 2018 , 25, e539-e544	2
632	Cutaneous comorbidities in patients with multiple myeloma: A 10-year retrospective cohort study from a Korean population. 2018 , 97, e12825	2
631	Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials. 2018 , 9, 23704-23717	12
630	Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation. 2018 , 54, 096-105	
629	Post-Transplantation Management Strategies. 2018 ,	
628	Identifying Educational Needs and Practice Gaps of European Hematologists and Hematology Nurses in the Treatment and Management of Multiple Myeloma. 2018 , 2, e33	2
627	NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma. 2018 , 19,	13
626	Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations. 2018 , 183, 538-556	27
625	Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma. 2018 , 19,	20
624	Increasing therapy-related myeloid neoplasms in multiple myeloma. 2019 , 49, e13050	8
623	Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. 2018 , 124, 4342-4349	20
622	Down-regulation of miR-203a by lncRNA PVT1 in multiple myeloma promotes cell proliferation. 2018 , 14, 1333-1339	28
621	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. 2018 , 8, 125	17

620	Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia. 2018 , 10, 327-338		3
619	CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma. 2018 , 9, 2722		82
618	Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis. 2018 , 11, 123		6
617	Daratumumab plus lenalidomide and dexamethasone lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. 2018 , 103, 2088-2096		133
616	The orthopaedic burden of cancer care. 2018 , 29, 343-349		
615	Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. <i>Blood</i> , 2018 , 132, 2555-2563	2.2	37
614	Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. 2018 , 132, 9-16		11
613	Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial. 2018 , 109, 3245-3252		5
612	Down-regulated G protein-coupled receptor kinase 6 leads to apoptosis in multiple myeloma MM1R cells. 2018 , 16, 4253-4259		0
611	Prognostic factors for multiple myeloma in the era of novel therapies. 2018 , 11, 863-879		16
610	Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicities. 2018 , 11, 957-973		6
609	Ixazomib: a novel drug for multiple myeloma. 2018 , 11, 761-771		13
608	Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms. 2018 , 9, 1058		25
607	Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA: A Pilot Study. 2018 , 20, 859-870		24
606	Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma. 2018 , 2, 1120-1128		11
605	A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. 2018 , 108, 267-273		1
604	Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat. 2018 , 18, 501-507		12
603	Pathway-structured predictive modeling for multi-level drug response in multiple myeloma. 2018 , 34, 3609-3615		2

602	Role of oral examination in newly diagnosed multiple myeloma patients: A safe and simple way to detect light chain amyloidosis. 2018 , 24, 1343-1348	5
601	Determining treatment intensity in elderly patients with multiple myeloma. 2018 , 18, 917-930	9
600	Multiple Liver Nodules Mimicking Metastatic Disease as Initial Presentation of Multiple Myeloma. 2018 , 2018, 7954816	4
599	High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS. 2018 , 97, 1879-1887	0
598	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. 2018 , 18, e401-e419	37
597	Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. 2018 , 182, 231-244	23
596	Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells. 2018 , 17, 985-996	11
595	Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. 2018 , 103, e544-e548	9
594	Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. 2018 , 101, 794-808	67
593	Maintenance and continuous therapy for multiple myeloma. 2018 , 18, 751-764	9
592	ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo. 2018 , 13, e0199517	7
591	Clinical observation of recombinant human endostatin in treating relapsed refractory multiple myeloma. 2018 , 45, 1325-1327	
590	Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury: a Case Series. 2018 , 43, 1263-1272	12
589	Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells. 2018 , 9, 334	16
588	Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects. 2018 , 9, 2943	16
587	Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice. 2018 , 101, 556-565	8
586	Targeting Bcl-2 for the treatment of multiple myeloma. 2018 , 32, 1899-1907	72
585	Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model. 2018 , 10,	12

584	Metabolic Features of Multiple Myeloma. 2018 , 19,	27
583	Anti-Proliferative Activity of HPOB against Multiple Myeloma Cells via p21 Transcriptional Activation. 2018 , 23,	4
582	Prognostic Value of Baseline F-Fluorodeoxyglucose PET/CT in Patients with Multiple Myeloma: A Multicenter Cohort Study. 2018 , 19, 481-488	8
581	The next generation of therapy for multiple myeloma: a review of ongoing clinical trials utilizing ClinicalTrials.gov. 2018 , 14, 1965-1976	4
580	Predicting multi-level drug response with gene expression profile in multiple myeloma using hierarchical ordinal regression. 2018 , 18, 551	7
579	Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. 2018 , 130, 27-35	17
578	Longitudinal Flow Cytometry Identified "Minimal Residual Disease" (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma. 2018 , 24, 2568-2574	22
577	Comparison of autologous hematopoietic cell transplantation performed in tandem and in disease relapse in multiple myeloma patients. 2018 , 65, 952-957	1
576	Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP). 2018 , 10,	43
575	Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen. 2018 , 35, 76-83	1
574	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. 2018 , 18, 533-540	7
573	The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience. 2018 , 101, 354-361	7
572	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. 2018 , 5, e563-e598	62
571	Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy. 2018 , 53, 1589-1592	4
570	Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma. 2019 , 111, 78-85	12
569	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. 2019 , 54, 353-367	51
568	A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1. 2019 , 185, 350-353	2
567	Cu-catalyzed oxygenation of alkene-tethered amides with O unactivated C[double bond, length as m-dash]C bond cleavage: a direct approach to cyclic imides. 2019 , 10, 9099-9103	15

566	Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells. 2019 , 110, 3275-3287	13
565	Cost-effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China. 2019 , 8, 979-992	1
564	Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States. 2019 , 125, 4084-4095	5
563	Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review. 2019 , 8, 215-221	4
562	Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. 2019 , 17, 100243	10
561	Palliative Care in Patients With Multiple Myeloma. 2019 , 58, 1113-1118	4
560	Efficacy and toxicity of histone deacetylase inhibitors in relapsed/refractory multiple myeloma: Systematic review and meta-analysis of clinical trials. 2019 , 18, 1057-1068	9
559	Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy. 2019 , 103, 393-401	8
558	Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective. 2019 , 12, 5813-5822	16
557	Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma. 2019 , 186, 807-819	6
556	Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma. 2019 , 10, 2040620719854171	7
555	Staging System to Predict the Risk of Relapse in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. 2019 , 9, 633	11
554	Superior Survival in African American Patients Who Underwent Autologous Stem Cell Transplantation for Multiple Myeloma. 2019 , 19, e506-e511	1
553	Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network. 2019 , 9, 83	4
552	Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. 2019 , 19, 921-928	3
551	Second-generation immunomodulatory drugs in leptomeningeal myeloma. 2019 , 60, 550-552	1
550	1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China. 2019 , 24, e1132-e1140	7
549	The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. 2019 , 19, 855	1

548	Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis. 2019 , 14, e0222522	0
547	Epidemiology of Multiple Myeloma. 2019 ,	1
546	Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience. 2019 , 39, 51	1
545	Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines. 2019 , 519, 597-604	7
544	Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma. 2019 , 98, 813-822	23
543	MiR-657/ATF2 Signaling Pathway Has a Critical Role in Dunn Extract-Induced Apoptosis in U266 and U937 Cells. 2019 , 11,	13
542	The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. 2019 , 98, 713-722	18
541	Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism. 2019 , 9, 1056	13
540	Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma. 2019 , 185, 11-24	12
539	Pumpless platform for high-throughput dynamic multicellular culture and chemosensitivity evaluation. 2019 , 19, 254-261	9
538	Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma. 2019 , 110, 228-236	3
537	Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. 2019 , 186, 549-560	43
536	Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?. 2019 , 19, 585-592.e1	0
535	Circulating microRNAs and Their Role in Multiple Myeloma. 2019 , 5,	5
534	Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. 2019 , 125, 2991-3000	47
533	Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. 2019 , 19, e415-e424	6
532	Plasmacytoma as a cause of small bowel obstruction in a virgin abdomen in a patient with multiple myeloma: a case report. 2019 , 13, 148	4
531	Geriatric Assessment and Frailty Scores Predict Mortality in Myeloma: Systematic Review and Meta-analysis. 2019 , 19, 488-496.e6	8

530	Serum protein N-glycosylation changes in multiple myeloma. 2019 , 1863, 960-970	16
529	Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study. 2019 , 19, 264	16
528	Epigenetic-Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease. 2019 , 3, e10183	13
527	Natural history of multiple myeloma with de novo del(17p). 2019 , 9, 32	22
526	Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study. 2019 , 98, 1435-1440	21
525	Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. 2019 , 98, 1441-1447	10
524	Multiple myeloma epidemiology and patient geographic distribution in Canada: A population study. 2019 , 125, 2435-2444	18
523	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. 2019 , 25, 1492-1497	17
522	Relapsed multiple myeloma manifesting as extramedullary plasmacytoma of the breast: Imaging findings. 2019 , 14, 584-587	6
521	Digital Tomosynthesis and Fractal Analysis Predict Prevalent Vertebral Fractures in Patients With Multiple Myeloma: A Preliminary In Vivo Study. 2019 , 213, W38-W44	4
520	Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. 2019 , 9, 41	62
519	Multiple Myeloma: Current Advances and Future Directions. 2019 , 19, 255-263	14
518	Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. 2019 , 102, 389-394	12
517	Validating an algorithm for multiple myeloma based on administrative data using a SEER tumor registry and medical record review. 2019 , 28, 256-263	3
516	Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. 2019 , 98, 941-949	7
515	Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. 2019 , 104, 1440-1450	39
514	miR-221/222-Mediated Inhibition of Autophagy Promotes Dexamethasone Resistance in Multiple Myeloma. 2019 , 27, 559-570	33
513	Substratification of patients with newly diagnosed standard-risk multiple myeloma. 2019 , 185, 254-260	8

512	Myeloma Associated Glomerular Disease. 2019 , 617-631	
511	Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population. 2019 , 14, 70-82	10
510	The pharmacologic management of multiple myeloma in older adults. 2019 , 20, 887-902	6
509	RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation. 2019 , 33, 2006-2021	19
508	Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France. 2019 , 2019, 4625787	6
507	CAR T-cell therapy: is it prime time in myeloma?. 2019 , 2019, 260-265	10
506	Impact of acquired del(17p) in multiple myeloma. 2019 , 3, 1930-1938	20
505	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. 2019 , 3, 744-750	15
504	Enrichment of circulating myeloma cells by immunomagnetic beads combined with flow cytometry for monitoring minimal residual disease and relapse in patients with multiple myeloma. 2019 , 98, 2769-2780	4
503	Supervised and home-based physical exercise in patients newly diagnosed with multiple myeloma-a randomized controlled feasibility study. 2019 , 5, 130	11
502	Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma. 2019 , 11,	5
501	Immunotherapy for Multiple Myeloma. 2019 , 11,	9
500	Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. 2019 , 8,	55
499	Current opinions in nephrology and hypertension: kidney transplantation in patients with plasma cell dyscrasias. 2019 , 28, 573-580	4
498	GENESIS: Phase III trial evaluating BL-8040+ ^γ G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma. 2019 , 15, 3555-3563	12
497	Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China. 2019 , 98, e17147	3
496	Stem-cell transplantation in multiple myeloma: how far have we come?. 2019 , 10, 2040620719888111	7
495	A Retrospective Analysis: A Novel Index Predicts Survival and Risk-Stratification for Bone Destruction in 419 Newly Diagnosed Multiple Myelomas. 2019 , 12, 10587-10596	2

494	Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries. 2019 , 19, e43-e50		10
493	Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor states. 2019 , 48, 773-779		8
492	Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. 2019 , 19, 9-22		15
491	Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway. 2019 , 444, 45-59		11
490	Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing. <i>Blood</i> , 2019 , 133, 652-659	2.2	27
489	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. 2019 , 94, 400-407		15
488	Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. 2019 , 125, 750-760		26
487	Design, synthesis and evaluation of anti-CD38 antibody drug conjugate based on Daratumumab and maytansinoid. 2019 , 27, 479-482		9
486	Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. 2019 , 49, 92-95		8
485	Navigating the treatment landscape in multiple myeloma: which combinations to use and when?. 2019 , 98, 1-18		40
484	Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. 2019 , 125, 550-558		4
483	3-Bromopyruvate as a potent anticancer therapy in honor and memory of the late Professor André Goffeau. 2019 , 36, 211-221		10
482	Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era. 2019 , 98, 963-970		7
481	Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. 2019 , 60, 619-628		5
480	Montelukast enhances cytotoxic effects of carfilzomib in multiple myeloma by inhibiting mTOR pathway. 2019 , 20, 381-390		4
479	Emerging roles of noncoding RNAs in multiple myeloma: A review. 2019 , 234, 7957-7969		7
478	RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells. 2019 , 19, 133-141		7
477	Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France. 2019 , 19, e13-e28		19

476	A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma. 2019 , 109, 107-114	5
475	Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987-2013. 2020 , 146, 35-43	7
474	Polypharmacy and potentially inappropriate medication use is highly prevalent in multiple myeloma patients and is improved by a collaborative physician-pharmacist clinic. 2020 , 26, 536-542	7
473	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. 2020 , 105, 468-477	27
472	Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation. 2020 , 55, 419-430	5
471	Strategies to improve patient-reported outcome completion rates in longitudinal studies. 2020 , 29, 335-346	11
470	Organ dose and total effective dose of whole-body CT in multiple myeloma patients. 2020 , 49, 549-554	6
469	A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. 2020 , 34, 224-233	54
468	A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. 2020 , 105, 201-208	20
467	Minimal residual disease in multiple myeloma 2019. 2020 , 3, e71	1
466	Factors influencing supportive care needs of multiple myeloma patients treated with chemotherapy. 2020 , 28, 1783-1791	1
465	The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. 2020 , 61, 680-690	6
464	Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis. 2020 , 111, 103-111	1
463	Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma. 2020 , 111, 57-64	1
462	Clinical effects of CD45 on the prognosis of extramedullary myeloma relapse. 2020 , 45, 144-151	0
461	Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells. 2020 , 20, 63-71	7
460	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. 2020 , 20, 53-56	5
459	Prognosis value of RBBP8 expression in plasma cell myeloma. 2020 , 27, 22-29	4

458	Risk Stratification in Multiple Myeloma in Indian Settings. 2020 , 36, 464-472	1
457	How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review. 2020 , 29, 1419-1431	8
456	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. 2020 , 95, 310-315	16
455	Multiple myeloma: Role of autologous transplantation. 2020 , 82, 101929	21
454	Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. 2020 , 61, 691-698	9
453	SOX12 promotes the growth of multiple myeloma cells by enhancing Wnt/ β -catenin signaling. 2020 , 388, 111814	7
452	Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. 2020 , 21, 29-41	9
451	Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN). 2020 , 146, 749-759	5
450	Primary Care Physician Perspectives on Caring for Adult Survivors of Hematologic Malignancies and Hematopoietic Cell Transplantation. 2020 , 20, 70-77	6
449	Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review. 2020 , 6, 425-432	25
448	Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data. 2020 , 9, 626-639	3
447	Development of a Patient Centered Outcome Set for Patients With Multiple Myeloma to be Used in Clinical Practice. 2020 , 4, e366	0
446	Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma. 2020 , 4, e380	2
445	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. 2020 , 10, 93	7
444	Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics. 2020 , 20, 699	2
443	How I manage frontline transplant-eligible multiple myeloma in Italy. 2020 , 12, 8954	
442	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. 2020 , 8,	13
441	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. 2020 , 396, 186-197	151

440	Exosomes in the Pathogenesis and Treatment of Multiple Myeloma in the Context of the Bone Marrow Microenvironment. 2020 , 10, 608815	13
439	Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment. 2020 , 13,	2
438	CAR T-Cells in Multiple Myeloma Are Ready for Prime Time. 2020 , 9,	9
437	Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients. 2020 , 10, 20846	4
436	Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma. 2020 , 61, 3101-3111	1
435	Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study. 2020 , 25, 2151-2157	1
434	Isatuximab for the treatment of relapsed/refractory multiple myeloma. 2020 , 20, 1395-1404	12
433	Eligibility of real-world patients with metastatic breast cancer for clinical trials. 2020 , 54, 171-178	2
432	Clinical impact of echocardiography-defined pulmonary hypertension on the clinical outcome in patients with multiple myeloma. 2020 , 99, e22952	2
431	Allogeneic Hematopoietic Transplantation for Multiple Myeloma in the New Drugs Era: A Platform to Cure. 2020 , 9,	3
430	Temporal Trends in Population-Level Cure of Cancer: The Australian Context. 2020 , 29, 625-635	4
429	Health-related quality of life of patients with multiple myeloma: A real-world study in China. 2020 , 9, 7896-7913	4
428	How I manage frontline transplant-ineligible multiple myeloma. 2020 , 12, 8956	2
427	Emerging immunotherapies in multiple myeloma. 2020 , 370, m3176	27
426	Inhibition of Multiple Myeloma Using 5-Aza-2'-Deoxycytidine and Bortezomib-Loaded Self-Assembling Nanoparticles. 2020 , 12, 6969-6976	1
425	Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice. 2020 , 10,	5
424	Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma. 2020 , 34, 2821-2828	1
423	Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients. 2020 , 10, 570187	3

422	In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells. 2020 , 8, 29	6
421	Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data. 2020 , 11, 561601	4
420	Characterizing Pain Experiences: African American Patients With Multiple Myeloma Taking Around-the-Clock Opioids. 2020 , 24, 538-546	3
419	Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. 2020 , 12,	6
418	Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017. 2020 , 191, 418-425	11
417	Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom. 2020 , 105, 308-325	4
416	Bortezomib use and outcomes for the treatment of multiple myeloma. 2020 , 50, 1059-1066	2
415	New drugs in early development for treating multiple myeloma: all that glitters is not gold. 2020 , 29, 989-1004	3
414	Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma. 2020 , 8, 14	12
413	A systematic review of economic evaluations of treatment regimens in multiple myeloma. 2021 , 21, 799-809	1
412	Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. 2021 , 106, 1957-1967	6
411	Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma. 2020 , 20, e474-e484	3
410	BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib and by promoting mitochondrial pathway-mediated cell apoptosis. 2020 , 11, 2040620720932686	5
409	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. 2020 , 13, 421-433	16
408	Developments in consolidation and maintenance strategies in post-remission multiple myeloma. 2020 , 13, 351-362	2
407	Clinical outcomes and prognostic factors in patients with multiple myeloma in South Tyrol: a retrospective single-center analysis. 2020 , 99, 1031-1040	1
406	Extramedullary Disease in Multiple Myeloma. 2020 , 15, 62-71	14
405	Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone. 2020 , 60, 1061-1075	2

404	Kidney transplant in multiple myeloma, the challenges, and potentials. 2020 , 4, 15-17	0
403	The Possible Role of Point Mutations and Activation of the CDC27 Gene in Progression of Multiple Myeloma. 2020 , 26, 100761	0
402	Characterization of resistance to a recombinant hexameric Fas-ligand (APO010) in human cancer cell lines. 2020 , 87, 33-41.e4	1
401	Aspirin exerts anti-tumor effect through inhibiting Blimp1 and activating ATF4/CHOP pathway in multiple myeloma. 2020 , 125, 110005	6
400	Heat shock proteins as a new, promising target of multiple myeloma therapy. 2020 , 13, 117-126	4
399	Timeliness of Initial Therapy in Multiple Myeloma: Trends and Factors Affecting Patient Care. 2020 , 16, e341-e349	4
398	Temporal trends in loss of life expectancy after a cancer diagnosis among the Australian population. 2020 , 65, 101686	6
397	LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation. 2020 , 55, 1736-1743	6
396	Multiple Myeloma: Available Therapies and Causes of Drug Resistance. 2020 , 12,	62
395	Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma. 2020 , 111, 673-680	3
394	Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. 2020 , 20, e221-e238	7
393	Tracking myeloma tumor DNA in peripheral blood. 2020 , 33, 101146	1
392	Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide. 2020 , 9, 1694-1702	1
391	Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. 2020 , 55, 1137-1146	6
390	Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A Prospective Single-arm Clinical Trial. 2020 , 59, 1149-1153	4
389	Maintenance Strategies After Hematopoietic Cell Transplantation. 2020 , 40, 727-740	0
388	Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study. 2020 , 61, 1669-1677	4
387	Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment. 2020 , 105, 196-202	6

386	Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy. 2020 , 9,	9
385	Long-term outcomes after autologous stem cell transplantation for multiple myeloma. 2020 , 4, 422-431	30
384	Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. 2020 , 4, 830-844	21
383	Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. 2021 , 35, 201-214	29
382	The Association between Metabolic Syndrome and Multiple Myeloma. 2021 , 144, 24-33	7
381	Multiple myeloma with CD138 changed from positive to negative: A case report. 2021 , 100, 249-253	2
380	Approaching the first relapse after autologous transplant in multiple myeloma. 2021 , 4,	
379	Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population-based study. 2021 , 10, 462-470	5
378	Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials. 2021 , 27, 887-896	4
377	Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma. 2021 , 21, e212-e219	1
376	Changes in treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from German claims database. 2021 , 106, 148-157	1
375	Monoclonal antibodies as an addition to current myeloma therapy strategies. 2021 , 21, 33-43	4
374	A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. 2021 , 39, 41-50	7
373	Design, synthesis and biological evaluation of thioether-containing lenalidomide and pomalidomide derivatives with anti-multiple myeloma activity. 2021 , 209, 112912	3
372	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. 2021 , 22, 142-154	22
371	HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells. 2021 , 20, 367-378	21
370	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. 2021 , 96, 330-337	3
369	Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn. 2021 , 93, 61-69.e4	0

368	Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma. 2021 , 62, 125-135	0
367	Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. 2021 , 11, 5	1
366	Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan. 2021 , 11, 1112	2
365	Use of bisphosphonates in multiple myeloma patients in Denmark, 2005-2015. 2021 , 29, 4501-4511	
364	Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. 2021 , 28, 640-660	13
363	Old and new generation immunomodulatory drugs in multiple myeloma. 2020 , 62, 207-219	2
362	HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma. 2021 , 22,	4
361	Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma. 2021 , 010-015	
360	The status of jaw lesions and medication-related osteonecrosis of jaw in patients with multiple myeloma. 2021 , 120, 1967-1976	2
359	Prognostic value of integrated cytogenetic, somatic variation, and copy number variation analyses in Korean patients with newly diagnosed multiple myeloma. 2021 , 16, e0246322	1
358	Role of Stem Cell Transplantation in Multiple Myeloma. 2021 , 13,	6
357	Chemotherapy-based regimens in multiple myeloma in 2020. 2021 , 63, 7-12	3
356	The microRNA miR-19a-3p suppresses cell growth, migration, and invasion in multiple myeloma via the Wnt/ β -catenin pathway.. 2021 , 10, 1053-1064	1
355	Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels. 2021 , 138, 155358	10
354	HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients. 2021 , 11, 599532	0
353	Radiation exposure and establishment of diagnostic reference levels of whole-body low-dose CT for the assessment of multiple myeloma with second- and third-generation dual-source CT. 2021 , 2841851211003287	
352	Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies. 2021 , 16, e0247717	2
351	Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients - a single centre experience. 2021 , 193, 420-423	2

350	Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. 2021 , 21, 154-161.e3	4
349	Validation of the Patient Dignity Inventory in Mexican Cancer Patients. 2021 , 24, 1626-1633	1
348	Novel Experimental Drugs for Treatment of Multiple Myeloma. 2021 , 13, 245-264	9
347	Role and Therapeutic Targeting of SDF-1/CXCR4 Axis in Multiple Myeloma. 2021 , 13,	5
346	The impact of changed treatment patterns in multiple myeloma on health-care utilisation and costs, myeloma complications, and survival: A population-based comparison between two time periods in Denmark. 2021 , 107, 63-73	
345	Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. 2021 , 27, 3695-3703	1
344	Survival Outcomes of Newly Diagnosed Multiple Myeloma at a Tertiary Care Center in North India (IMAGe: 001A Study). 2021 , 7, 704-715	1
343	Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. 2021 , 21, 606	8
342	Oral therapy adherence and satisfaction in patients with multiple myeloma. 2021 , 100, 1803-1813	0
341	Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. 2021 , 11, 94	11
340	Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma. 2021 , 41, 259-267	1
339	Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape. 2021 , 107, 92-103	
338	Differences in survival among multiple myeloma patients in the United States SEER population by neighborhood socioeconomic status and race/ethnicity. 2021 , 32, 1021-1028	0
337	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. 2021 , 8, e422-e432	17
336	Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma. 2021 , 13, 465-473	2
335	Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation. 2021 , 20, 1137-1145	1
334	The influence of high-efficiency particulate air filtration on mortality among multiple myeloma patients receiving autologous stem cell transplantation. 2021 , 11, 11789	1
333	Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System. 2021 , 38, 218-221	

332	Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. 2021 , 1	1
331	Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. 2021 , 15, 2401-2415	7
330	Clinical Outcomes Associated With Chronic Kidney Disease in Elderly Medicare Patients With Multiple Myeloma. 2021 , 21, 401-412.e24	1
329	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. 2021 , 21, 451-460.e2	2
328	Can Targeting Hypoxia-Mediated Acidification of the Bone Marrow Microenvironment Kill Myeloma Tumor Cells?. 2021 , 11, 703878	1
327	Smoldering multiple myeloma - Past, present, and future. 2021 , 100869	0
326	Long non-coding RNA DANCR represses the viability, migration and invasion of multiple myeloma cells by sponging miR-135b-5p to target KLF9. 2021 , 24,	3
325	Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies. 2021 , 21, 444-450.e3	2
324	Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma. 2021 , 12, 699629	1
323	A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival. 2021 , 195, 217-229	1
322	Multiples Myelom mit Zerstörung des Ellenbogengelenks: Lang anhaltende Symptomkontrolle und Funktionserhalt durch Strahlentherapie.	
321	The work of managing multiple myeloma and its implications for treatment-related decision making: a qualitative study of patient and caregiver experiences. 2021 , 21, 793	1
320	Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse. 2021 , 26, 2142-2150	3
319	Nivolumab Effective for Gastric and Lung Cancers but Not for Multiple Myeloma in a Multiple Primary Cancer Patient. 2021 , 2021, 9965371	
318	Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials. 2021 ,	0
317	CAR T-Cell Therapy in Hematological Malignancies. 2021 , 22,	9
316	Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study. 2021 , 57,	0
315	Racial disparities in hospitalization outcomes among adult multiple myeloma patients using the national inpatient sample (2016-2018). 2021 , 39, 724-727	1

314	Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On F-FDG PET/CT at Baseline. 2021,	
313	Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications. 2021, 13,	2
312	Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation. 2021, 8, 712070	2
311	The Extracellular NADome Modulates Immune Responses. 2021, 12, 704779	5
310	Targeting BCMA in Multiple Myeloma. 2021, 16, 367-383	0
309	Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis. 2021, 114, 599-607	2
308	Myeloid-derived peripheral blood suppressor cells at haematopoietic stem cell mobilisation in multiple myeloma patients. 2021, 66, 218-230	1
307	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. 2021, 17, 4797-4812	1
306	Cutaneous Multiple Myeloma. 2021, 13, e17779	
305	Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. 2021, 13,	3
304	Identification of Potential Prognostic Biomarker for Predicting Survival in Multiple Myeloma Using Bioinformatics Analysis and Experiments. 2021, 12, 722132	0
303	A novel form of anti-angiogenic molecular antibody drug induces apoptosis in myeloma cells after cultivation upon endothelial feeder cells. 2021, 108, 106617	0
302	Secondary primary malignancies in patients with multiple myeloma: A single institution experience. 2021, 39, 674-679	0
301	The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact. 2021, 1-11	1
300	Association Between Kidney Function, Proteinuria and the Risk of Multiple Myeloma: A Population-Based Retrospective Cohort Study in South Korea. 2021,	
299	Identification of new therapeutic targets of bone cancers by proteomic strategies. 2022, 783-803	
298	Utilization of radiation therapy in multiple myeloma: trends and changes in practice. 2021, 100, 735-741	
297	Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV). 2021, 147, 2349-2359	1

296	Energy Balance and Multiple Myeloma in African Americans. 2014 , 119-129	1
295	High-dose therapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma. 2011 , 183, 207-38	2
294	Therapy of relapsed and refractory multiple myeloma. 2011 , 183, 239-71	15
293	Monoclonal gammopathies. 2013 , 975-986	1
292	Mortality by a proxy performance status as defined by a claims-based measure for disability status in older patients with newly diagnosed multiple myeloma in the United States. 2019 , 10, 490-496	2
291	Current status of aut mobilization in Myeloma. 2017 , 56, 850-853	6
290	Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma. 2010 , 21, 708-15	8
289	Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS). 2018 , 2, e45	21
288	Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy. 2021 , 193, 101-112	3
287	Whole Body Low Dose Computed Tomography Using Third-Generation Dual-Source Multidetector With Spectral Shaping: Protocol Optimization and Literature Review. 2020 , 18, 1559325820973131	7
286	Evidence-Based Mini-Review: Treatment Options for Patients with Relapsed/Refractory Myeloma Previously Treated with Novel Agents and High-Dose Chemotherapy and Autologous Stem-Cell Transplantation. 2010 , 2010, 310-313	2
285	New Insights into Therapeutic Targets in Myeloma. 2011 , 2011, 184-190	9
284	CAR T-cell therapy: is it prime time in myeloma?. 2019 , 3, 3473-3480	11
283	Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment. 2013 , 17, E35-44	2
282	Novel approaches to treatment of double-refractory multiple myeloma. 2013 ,	16
281	Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma. 2012 , 7, e52398	22
280	Very late antigen-4 (VLA-4) (CD11) Integrin) targeted PET imaging of multiple myeloma. 2013 , 8, e55841	29
279	Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. 2013 , 8, e64354	34

278	Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors. 2013 , 8, e83905	16
277	Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. 2014 , 9, e103015	22
276	Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. 2015 , 10, e0138248	4
275	Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma. 2017 , 12, e0174835	24
274	Echocardiography-Defined Pulmonary Hypertension in Multiple Myeloma: Risk Factors and Impact on Outcomes. 2016 , 109, 282-9	4
273	Maintenance therapy for myeloma: how much, how long, and at what cost?. 2012 , 515-22	3
272	Intracranial Involvement in Multiple Myeloma Presenting as a Cranial Nerve Palsy. 2019 , 8, 29-33	4
271	Iron in multiple myeloma. 2013 , 18, 449-61	9
270	Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens. 2015 , 8, e3755	8
269	Multiple myeloma cell lines and primary tumors proteoma: protein biosynthesis and immune system as potential therapeutic targets. 2015 , 6, 462-471	15
268	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. 2016 , 7, 59029-59048	14
267	The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo. 2016 , 7, 62572-62584	3
266	Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells. 2017 , 8, 3396-3411	47
265	A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma. 2017 , 8, 41538-41548	18
264	Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties. 2017 , 8, 53053-53067 ²⁰	
263	Hedgehog signaling sensitizes glioma stem cells to endogenous nano-irradiation. 2014 , 5, 5483-93	24
262	Multiple myeloma cell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. 2014 , 5, 5686-99	52
261	Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. 2014 , 5, 10237-50	20

260	Polymorphisms in the promoter region of the gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients. 2018 , 9, 24054-24068	5
259	Increased circulating CD4FOXP3 T cells associate with early relapse following autologous hematopoietic stem cell transplantation in multiple myeloma patients. 2018 , 9, 27305-27317	5
258	N-terminal pro-brain natriuretic peptide reflects both left ventricular diastolic dysfunction and myeloma-related renal insufficiency and robustly predicts mortality in patients with symptomatic multiple myeloma. 2019 , 10, 1160-1170	1
257	The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression. 2019 , 10, 5480-5491	5
256	Radioimmunotherapy with ⁹⁰ Y-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma. 2015 , 6, 4692-703	38
255	Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma. 2015 , 6, 26922-34	17
254	Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I. 2015 , 6, 26982-94	19
253	HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. 2015 , 6, 31134-50	29
252	UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression. 2015 , 6, 40704-18	26
251	Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. 2016 , 7, 4062-76	26
250	The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential. 2016 , 7, 48732-48752	26
249	Epidemiology of Multiple Myeloma in Novosibirsk (Siberian Federal District). 2018 , 12, 86-94	5
248	Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. 2010 , 10, 116-20	32
247	Barriers and Facilitators of Using Sensored Medication Adherence Devices in a Diverse Sample of Patients With Multiple Myeloma: Qualitative Study. 2018 , 4, e12	3
246	The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study. 2019 , 1, 220-228	3
245	Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers?. 2020 , 2, 133-142	1
244	Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. 2019 , 23, 1-94	2
243	Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma. 2021 , 106, 2013-2017	1

242	The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. 2020 , 14,	5
241	The Current Status and Future of Multiple Myeloma in the Clinic. 2010 , 10, E1-E16	8
240	Downregulation of DCC sensitizes multiple myeloma cells to bortezomib treatment. 2019 , 19, 5023-5029	1
239	Recent advances in multiple myeloma: a Korean perspective. 2016 , 31, 820-34	15
238	Multiple myeloma : recent progress in diagnosis and treatment. 2012 , 52, 149-59	18
237	Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment. 2019 , 36, 106-111	2
236	Frontline therapy for newly diagnosed patients with multiple myeloma. 2020 , 55, S37-S42	5
235	Treatment approach of nontransplant patients with multiple myeloma. 2014 , 26, 348-51	6
234	Novel agents and new therapeutic approaches for treatment of multiple myeloma. 2014 , 4, 73-90	26
233	Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. 2015 , 13, 1398-435	51
232	Once-weekly subcutaneous administration of bortezomib in patients with multiple myeloma. 2015 , 16, 2093-8	11
231	Supportive care in multiple myeloma: Current practices and advances. 2021 , 29, 100476	
230	Trends, Sociodemographic and Hospital-Level Factors Associated With Palliative Care Utilization Among Multiple Myeloma Patients Using the National Inpatient Sample (2016-2018). 2021 , 10499091211051667	1
229	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. 2021 ,	5
228	A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. 2021 , 14, 161	14
227	Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: A network meta-analysis. 2021 , 168, 103504	0
226	Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989-2018. 2021 ,	2
225	Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium. 2021 , 11,	1

- 224 Treatment of Multiple Myeloma: A Comprehensive Review. **2009**, 3, 65-75
- 223 Plasma Cell Tumors: Multiple Myeloma And Solitary Plasmacytoma. **2010**, 1394-1399
- 222 Multiple Myeloma. 577-598
- 221 The Role of Centrosomes in Multiple Myeloma. **2012**, 255-276 1
- 220 Successful Treatment of Low-Dose Lenalidomide Maintenance Therapy Followed by Second Autologous Peripheral Blood Stem Cell Transplantation in Heavily Treated Multiple Myeloma. **2012**, 03, 106-109
- 219 Hematology. **2012**, 767-871
- 218 Migration and Homing in Multiple Myeloma. **2013**, 215-239
- 217 Genomic Strategies Determining Progression from MGUS to Multiple Myeloma. **2013**, 3-24
- 216 Role of Bone Disease in the Pathogenesis of Multiple Myeloma. **2013**, 97-120 0
- 215 Novel Agents in Multiple Myeloma. **2013**, 215-228
- 214 Early Combination Studies in Multiple Myeloma. **2013**, 229-255
- 213 Harnessing Allogeneic Immunity for Anti-myeloma Response. **2013**, 111-129
- 212 Newer IMiDs. **2013**, 181-213
- 211 Multiple Myeloma Surveillance Counterpoint: Canada. **2013**, 503-509
- 210 Myeloma Bone Disease. **2014**, 211-223
- 209 Management of Treatment Complications and Supportive Care. **2014**, 159-177
- 208 Allogeneic Stem Cell Transplantation. **2014**, 125-129
- 207 Molecular Classification and Risk Stratification. **2014**, 55-64

206 Future directions. **2013**, 114-135

205 Multiple myeloma. **2014**, 135-145

204 Multiple Myeloma and Other Hematological Malignancies. **2014**, 1335-1354

203 Changes in P-glycoprotein during Treatment with Anti-cancer Drug and its Influence on Pharmacokinetics and Pharmacological Effects. **2014**, 40, 193-207 1

202 Biology and Treatment of Skeletal Manifestations in Multiple Myeloma. **2014**, 05, 387-402

201 Multiple Myeloma and the Kidney. **2014**, 303-310

200 Multiple Myeloma and Related Disorders. **2014**, 1991-2017.e7 1

199 Proteasome Inhibitors in the Treatment of Multiple Myeloma and AL Amyloidosis. **2014**, 99-115

198 Multiple Myeloma. **2015**, 203-218

197 Dose-adjustment of lenalidomide according to patient age and vulnerability is feasible in relapsed or refractory multiple myeloma: retrospective analysis of 20 cases. **2014**, 5, 1

196 Emerging role of patients in clinical research. **2014**, 65-86

195 Multiple myeloma. **2014**, 679-702

194 Gemcitabine in treating patients with refractory or relapsed multiple myeloma. **2014**, 15, 9291-3 2

193 Novel Agents for Treatment of Multiple Myeloma. **2015**, 88, 252

192 The Role of PI3K/AKT/mTOR Inhibitors in the Treatment of Hematological Malignancies. **2016**, 139-160

191 High Cut Off Hemodialysis. **2016**, 257-268

190 Clinical Features, Management, and Therapy of Plasma Cell Neoplasms: What Pathologists Need to Know. **2016**, 9-34

189 Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins. **2016**, 7, 67061-67070

- 188 Plasma Cell Leukemia. **2017**, 1-16
- 187 Plasmacytoma and Multiple Myeloma. **2017**, 85-96
- 186 Elotuzumab for Treatment of Multiple Myeloma (Literature Review). **2016**, 9, 438-445
- 185 Myeloma Associated Glomerular Disease. **2017**, 1-15
- 184 Stem Cell Transplantation for Multiple Myeloma. **2017**, 73-86
- 183 Lymphoma and Myeloma of the Sacrum. **2017**, 227-235
- 182 The news in multiple myeloma treatment. **2017**, 19, 20-22 ○
- 181 Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of Double Refractory Multiple Myeloma. **2017**, 10, 372-380 ○
- 180 A computational model of MGUS progression to Multiple Myeloma identifies optimum screening strategies and their effects on mortality.
- 179 Practical Considerations for Bone Health in Multiple Myeloma. **2018**, 131-167
- 178 Risk Stratification in Newly Diagnosed Transplant Ineligible Multiple Myeloma. **2018**, 37-58
- 177 DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA. **2017**, 94-102
- 176 Barriers and Facilitators of Using Sensored Medication Adherence Devices in a Diverse Sample of Patients With Multiple Myeloma: Qualitative Study (Preprint).
- 175 Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of New Drugs. **2018**, 11, 187-191
- 174 RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.
- 173 Magnetic Resonance Imaging of Bone Marrow and its Results as a Criterion for Administration of Maintenance Therapy After Auto-HSCT in Multiple Myeloma Patients. **2018**, 11, 360-367
- 172 Therapy for relapsed multiple myeloma. **2018**, 60, 174-184 1
- 171 Nowe terapie w leczeniu szpiczaka z wysokim ryzykiem cytogenetycznym. **2018**, 49, 102-111

- 170 Pathophysiology of Cancer Pain. **2019**, 13-17
- 169 Minimal Residual Disease Assessment in Myeloma. **2019**, 231-245
- 168 Moving Toward Continuous Therapy in Multiple Myeloma. **2019**, 1, 189-200 3
- 167 The Value Of International Staging System In Predicting Survival of Multiple Myeloma Patients With Renal Failure. 237-242
- 166 Factors Associated with Dose Modification of Lenalidomide Plus Dexamethasone Therapy in Multiple Myeloma. **2020**, 43, 1253-1258 0
- 165 Daratumumab utilization and cost analysis among patients with multiple myeloma in a US community oncology setting. **2021**,
- 164 Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth. **2021**, 2
- 163 Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance. **2021**, 1
- 162 Diagnosis and Treatment of Multiple Myeloma for Spinal Surgeons. **2020**, 34, 134-138
- 161 Multiple myeloma: an update. **2020**, 3, 72 2
- 160 Parametric and Non-Parametric Analysis of the Survival Times of Patients with Multiple Myeloma Cancer. **2020**, 10, 118-134 1
- 159 Pro-kidney transplantation should be considered in patients with multiple myeloma. **2020**, 4, 18-21 1
- 158 Hematological Neoplasia. **2008**, 400-526
- 157 Prognostic value of the modified multiple myeloma comorbidity index in real clinical practice. **2020**, 15, 51-62
- 156 Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma. **2020**, 11, 3984-3997 1
- 155 Relapsed/Progressive Disease and Its Prognostic Factors among Multiple Myeloma Patients Receiving Novel Agent Treatment in North East Peninsular Malaysia: A Single Centre Experience. **2020**, 27, 62-77
- 154 Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. **2009**, 30, 93-103 15
- 153 Update in hematology. **2011**, 6, 62-3

152	Novel treatment paradigm for elderly patients with multiple myeloma. 2011 , 1, 190-204	8
151	Multiple myeloma. 2012 , 9, 150-2	8
150	Determining the optimal time for bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplant in the treatment of multiple myeloma. 2013 , 25, 166-74	1
149	Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment. 2013 , 25, 155-60	5
148	Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs. 2013 , 10, 183-6	4
147	Innovative agents in multiple myeloma. 2014 , 5, 193-202	12
146	A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation. 2014 , 7, 6313-22	3
145	Top Information Need Priorities of Older Adults Newly Diagnosed With Active Myeloma. 2015 , 6, 14-21	6
144	MiR-301a promotes cell proliferation by directly targeting TIMP2 in multiple myeloma. 2015 , 8, 9168-74	12
143	Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma. 2016 , 9, 140-3	4
142	Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma. 2016 , 9, 93-6	1
141	Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. 2016 , 9, 102-5	10
140	Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma. 2016 , 9, 74-7	2
139	Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma. 2016 , 9, 70-3	9
138	Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma. 2016 , 9, 111-4	2
137	Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States. 2018 , 11, 39-46	9
136	BTK induces CAM-DR through regulation of CXCR4 degradation in multiple myeloma. 2019 , 11, 4139-4150	4
135	[Advances in the diagnosis and treatment of multiple myeloma]. 2018 , 39, 605-608	

- 134 [Retrospective study of the efficacy and safety of treatment with PDD vs PAD in de novo patients with multiple myeloma]. **2015**, 36, 340-3
- 133 [Efficacy and safety of CTD and PCD regimens in treatment of patients with newly diagnosed multiple myeloma]. **2017**, 38, 279-284
- 132 [The clinical value of diagnostic-driven therapy of invasive fungal disease (IFD) type unclassified CIIgroup in multiple myeloma patients during inducing chemotherapy]. **2018**, 39, 435-437
- 131 [Evaluation and comparison of prognostic value of serum free light chain ratio/difference in patients with newly diagnosed multiple myeloma]. **2019**, 40, 321-326
- 130 [Comparison of the efficacy and safety of Bortezomib between the twice-weekly and once-weekly regimens for newly diagnosed multiple myeloma]. **2017**, 38, 725-727
- 129 [Efficacy and prognosis of PAD combination therapy for fifty-six previously untreated patients with multiple myeloma]. **2016**, 37, 520-2
- 128 [Clinical features and prognosis of 93 elderly patients with multiple myeloma]. **2017**, 38, 744-748 ○
- 127 [Targeting BCMA in multiple myeloma using chimeric antigen receptor-engineered T cells]. **2019**, 40, 804-811 ○
- 126 [The effect of peripheral blood cell score on the prognosis of multiple myeloma patients treated with bortezomib]. **2020**, 41, 756-761
- 125 [The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China]. **2021**, 42, 628-634
- 124 NS-65: Introducing frailty assessment into a myeloma service [a Quality Improvement Project (QIP)]. **2021**, 21, S167-S168
- 123 Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis. **2021**, 13, ○
- 122 Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group. **2021**, 10,
- 121 Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. **2021**, 12, 6960 9
- 120 Kinetics of response to first- and second-line therapies in multiple myeloma: Assessment by both M-spikes and light chains. **2021**,
- 119 Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy. **2021**, 11, ○
- 118 Minimal residual disease in multiple myeloma: an important tool in clinical trials. **2021**,
- 117 Expression of PD-1 and TIM-3 inhibitory checkpoint molecules by T-lymphocytes in early post-transplant period in multiple myeloma patients. **2021**, 66, 499-511

116	Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-FDG PET/CT. 2021 , 11, 190	2
115	Multiples Myelom. 2016 , 1-17	
114	Prognostic value of F-fluorodeoxyglucose positron emission tomography/computed tomography at diagnosis in untreated multiple myeloma patients: a systematic review and meta-analysis.. 2022 , 1	
113	Pretransplant Determinants of Outcome in Patients with Myeloma Undergoing Autologous Transplantation in Lower Resource Settings. 101-110	
112	Epigenetic Modifications in Myeloma: Focused Review of Current Data and Potential Therapeutic Applications. 2021 , 42, 395-405	
111	Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma.. 2022 ,	0
110	Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma. 2022 , 44, 350-359	5
109	miR-140-3p attenuated the tumorigenesis of multiple myeloma via attenuating BZW2.. 2022 , 27, 173-180	0
108	Integrated Transcriptomic Analysis Reveals a Distinctive Role of YAP1 in Extramedullary Invasion and Therapeutic Sensitivity of Multiple Myeloma.. 2021 , 11, 787814	0
107	Single-Cell Transcriptomes Combining with Consecutive Genomics Reveal Clonal Evolution and Gene Regulatory Networks in Relapsed and Refractory Multiple Myeloma.. 2021 , 9, 794144	1
106	Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.. 2022 ,	0
105	GFI1-Dependent Repression of Increases Multiple Myeloma Cell Survival.. 2022 , 14,	1
104	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.. 2022 , 9, e143-e161	6
103	Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.. 2022 , 22, 147	
102	Practical guidance for new multiple myeloma treatment regimens: A nursing perspective.. 2022 ,	
101	Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?. 2022 , 11,	0
100	Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment.. 2022 , 12, 820768	0
99	A novel silicone derivative of natural osalmid (DCZ0858) exerts anti-multiple myeloma activity by promoting cell apoptosis and inhibiting cell cycle and mTOR signaling. 2021 , 13, 11439-11449	1

98	Drug resistance and minimal residual disease in multiple myeloma.. 2022 , 5, 171-183	0
97	Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study.. 2022 , 12, 34	3
96	Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019.. 2022 ,	1
95	Impact of quality of response on survival outcomes among multiple myeloma patients treated with novel agents - a retrospective analysis.. 2022 ,	
94	Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network).. 2022 , 12,	0
93	Promising therapeutic approaches for relapsed/refractory multiple myeloma.. 2022 , 27, 343-352	0
92	Editorial: Molecular Mechanisms of Multiple Myeloma.. 2022 , 12, 870123	
91	Exposure-Response Analyses for Selection/Confirmation of Optimal Isatuximab Dosing Regimen in Combination With Pomalidomide/Dexamethasone Treatment in Patients With Multiple Myeloma.. 2022 ,	0
90	Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen.. 2022 ,	0
89	Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma.. 2022 , 1	0
88	PDZ proteins SCRIB and DLG1 regulate myeloma cell surface CD86 expression, growth, and survival.. 2022 ,	0
87	Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma.. 2021 , 10, 5258-5266	1
86	Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myeloma.. 2021 ,	0
85	Anti CD38 monoclonal antibodies for multiple myeloma treatment.. 2022 , 1-9	0
84	Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis.. 2022 , 12, 66	0
83	Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option.. 2022 ,	2
82	Data_Sheet_1.PDF. 2019 ,	
81	DataSheet_1.docx. 2018 ,	

- 80 Presentation_1.PPTX. **2018**,
- 79 Presentation_2.PPTX. **2018**,
- 78 Presentation_3.PPTX. **2018**,
- 77 Presentation_4.PPTX. **2018**,
- 76 Presentation_5.PPTX. **2018**,
- 75 Presentation_6.PPTX. **2018**,
- 74 [Clinical analysis of 25 patients with non transplanted multiple myeloma who survived for more than 10 years].. **2022**, 43, 161-163
- 73 Prevalence and clinical correlates of cognitive impairment in adults with plasma cell disorders.. **2022**,
- 72 Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results.. **2022**, 1
- 71 Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience.. **2022**, 14, 0
- 70 Primary and Metastatic Bone Lesions. **2017**, 937-952.e3
- 69 Burden of arrhythmias and predictors of mortality among multiple myeloma patients with arrhythmias.. **2022**,
- 68 Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma.. **2022**, 13, 20406207221090089
- 67 Long-term CR Multiple Myeloma Patients Show Cured or MGUS-like Minimal Residual Disease Pattern by Next Generation Flow.. **2022**,
- 66 Gene therapy with B-cell maturation antigen/ CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma.
- 65 An update on novel multiple myeloma targets. 0
- 64 The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice. **2022**, 12, 0
- 63 Impact of Atrial Fibrillation on Inpatient Outcomes Among Hospitalized Patients With Multiple Myeloma. **2022**,

62	Multiple myeloma and cardiac amyloidosis. 2023 , 423-432	
61	Real-world effectiveness and safety analysis of carfilzomib lenalidomide dexamethasone and carfilzomib dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis. 2022 , 13, 204062072211045	o
60	Suprasellar Plasmacytoma Leading to the Diagnosis of Multiple Myeloma. 2022 ,	
59	CD38 Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma. 2022 ,	
58	The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. 2022 , 13,	o
57	Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol. 2022 , 12, e061808	o
56	Clinical Characteristics and Outcomes of IgD Myeloma: Experience across UK National Trials.	o
55	The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring "Multiple Myelomas" 2022 , 14, 3271	1
54	Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma. 2022 , 14, 3330	1
53	Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).	1
52	Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance. 12,	1
51	Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma. 2022 , 18, 2661-2674	o
50	High-Throughput CRISPR Screening in Hematological Neoplasms. 2022 , 14, 3612	o
49	PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo. 2022 , 215832	1
48	Prognostic Communication in the Era of Targeted Therapy and Immunotherapy.	
47	Bone Disease in Multiple Myeloma: Biologic and Clinical Implications. 2022 , 11, 2308	o
46	CyBORd-DARA in newly diagnosed transplant-eligible multiple myeloma: results from the 16-BCNI-001/CTRIAL-IE 16-02 study show high rates of MRD negativity at end of treatment. 2022 ,	1
45	Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant (HSCT) in Multiple Myeloma Patients: 5-year Experience from a Single Centre in North India.	o

44	Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life. 2022 ,	
43	Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. 2022 ,	
42	Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909).	○
41	Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments. 13,	○
40	I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients. 2022 , 12,	○
39	Steps towards a Multiple Myeloma Cure?. 2022 , 12, 1451	1
38	Radiomics Models Based on Magnetic Resonance Imaging for Prediction of the Response to Bortezomib-Based Therapy in Patients with Multiple Myeloma. 2022 , 2022, 1-9	○
37	Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.	○
36	The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study. 2022 , 22,	○
35	Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).	○
34	Patient-Derived Multiple Myeloma 3D Models for Personalized Medicine—Are We There Yet?. 2022 , 23, 12888	○
33	Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018. 2022 , 14, 4919	○
32	Plasma Cell Disorders. 1-30	○
31	Circulating Tumor DNA: Less Invasive, More Representative Method to Unveil the Genomic Landscape of Newly Diagnosed Multiple Myeloma Than Bone Marrow Aspirates. 2022 , 14, 4914	○
30	Graded Depth of Response and Neoplastic Plasma Cell Index as Indicators of Survival Outcomes in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant.	○
29	Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation. 10, 11712-11725	○
28	Expression levels and patterns of B-cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent.	○
27	An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma. 2022 , 13,	1

- 26 Development of multiple myeloma after 15 years of treatment for polycythemia vera and successful treatment using bortezomib: A case report. **2022**, 10,
- 25 Renal Involvement in Multiple Myeloma. 46-52
- 24 Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival.
- 23 Friends and foes of multiple myeloma measurable/minimal residual disease evaluation by next generation flow. 12,
- 22 Serum proteomic profiling reveals MTA2 and AGO2 as potential prognostic biomarkers associated with disease activity and adverse outcomes in multiple myeloma. **2022**, 17, e0278464
- 21 Survival trends and prognostic factors for patients with extramedullary plasmacytoma: A population-based study. 12,
- 20 Efficacy and Safety Analysis of VRD-PDCE in Treatment-Native Patients with Multiple Extramedullary Plasmacytomas or Plasma Cell Leukemia.
- 19 Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients. **2022**, 14, 6106
- 18 Pre-mobilization platelet count predicts stem cell yield during mobilization in patients with multiple myeloma. **2022**,
- 17 Generic lenalidomide Rivelime[®] versus brand-name Revlimid[®] in the treatment of relapsed/refractory multiple myeloma: A retrospective single-center experience on efficacy, safety and survival outcome. **2022**,
- 16 The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies.
- 15 Tandem autologous stem cell transplantation in elderly patients with myeloma: A multicenter retrospective analysis.
- 14 Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients. 1-9
- 13 Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients.
- 12 Metastatic infiltration of nervous tissue and periosteal nerve sprouting in multiple myeloma induced bone pain.
- 11 Dynamic single-cell RNA-seq analysis reveals distinct tumor program associated with microenvironmental remodeling and drug sensitivity in multiple myeloma. **2023**, 13,
- 10 Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma.
- 9 Real-world evidence of daratumumab-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: A single-center experience in Taiwan focusing on efficacy. **2023**, 10, 19

- 8 Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. ○
- 7 Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma. ○
- 6 Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. **2023**, 15, 1558 ○
- 5 Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. **2023**, 16, 415 ○
- 4 A survey of quality-of-life tools used in the routine care of patients with multiple myeloma. **2023**, 32, S10-S14 ○
- 3 Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors. **2023**, 24, 5730 ○
- 2 Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era. ○
- 1 CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies. **2023**, 40, ○